MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2:Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome by Jarius, Sven et al.
Syddansk Universitet
MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2
Jarius, Sven; Ruprecht, Klemens; Kleiter, Ingo; Borisow, Nadja; Asgari, Nasrin; Pitarokoili,
Kalliopi; Pache, Florence; Stich, Oliver; Beume, Lena-Alexandra; Hümmert, Martin W;
Ringelstein, Marius; Trebst, Corinna; Winkelmann, Alexander; Schwarz, Alexander;
Buttmann, Mathias; Zimmermann, Hanna; Kuchling, Joseph; Franciotta, Diego; Capobianco,
Marco; Siebert, Eberhard; Lukas, Carsten; Korporal-Kuhnke, Mirjam; Haas, Jürgen; Fechner,
Kai; Brandt, Alexander U.; Schanda, Kathrin; Aktas, Orhan; Paul, Friedemann; Reindl,
Markus; Wildemann, Brigitte; in cooperation with the Neuromyelitis Optica Study Group
(NEMOS)
Published in:
Journal of Neuroinflammation
DOI:
10.1186/s12974-016-0718-0
Publication date:
2016
Document version
Final published version
Document license
CC BY
Citation for pulished version (APA):
in cooperation with the Neuromyelitis Optica Study Group (NEMOS) (2016). MOG-IgG in NMO and related
disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and
laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 13, [280]. DOI:
10.1186/s12974-016-0718-0
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
RESEARCH Open Access
MOG-IgG in NMO and related disorders: a
multicenter study of 50 patients. Part 2:
Epidemiology, clinical presentation,
radiological and laboratory features,
treatment responses, and long-term
outcome
Sven Jarius1*, Klemens Ruprecht2, Ingo Kleiter3, Nadja Borisow4,5, Nasrin Asgari6, Kalliopi Pitarokoili3,
Florence Pache4,5, Oliver Stich7, Lena-Alexandra Beume7, Martin W. Hümmert8, Marius Ringelstein9, Corinna Trebst8,
Alexander Winkelmann10, Alexander Schwarz1, Mathias Buttmann11, Hanna Zimmermann2, Joseph Kuchling2,
Diego Franciotta12, Marco Capobianco13, Eberhard Siebert14, Carsten Lukas15, Mirjam Korporal-Kuhnke1,
Jürgen Haas1, Kai Fechner16, Alexander U. Brandt2, Kathrin Schanda17, Orhan Aktas8, Friedemann Paul4,5†,
Markus Reindl17†, and Brigitte Wildemann1†; in cooperation with the Neuromyelitis Optica Study Group (NEMOS)
Abstract
Background: A subset of patients with neuromyelitis optica spectrum disorders (NMOSD) has been shown to be
seropositive for myelin oligodendrocyte glycoprotein antibodies (MOG-IgG).
Objective: To describe the epidemiological, clinical, radiological, cerebrospinal fluid (CSF), and electrophysiological
features of a large cohort of MOG-IgG-positive patients with optic neuritis (ON) and/or myelitis (n = 50) as well as attack
and long-term treatment outcomes.
Methods: Retrospective multicenter study.
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Results: The sex ratio was 1:2.8 (m:f). Median age at onset was 31 years (range 6-70). The disease followed a multiphasic
course in 80% (median time-to-first-relapse 5 months; annualized relapse rate 0.92) and resulted in significant disability in
40% (mean follow-up 75 ± 46.5 months), with severe visual impairment or functional blindness (36%) and markedly
impaired ambulation due to paresis or ataxia (25%) as the most common long-term sequelae. Functional blindness in
one or both eyes was noted during at least one ON attack in around 70%. Perioptic enhancement was present in several
patients. Besides acute tetra-/paraparesis, dysesthesia and pain were common in acute myelitis (70%). Longitudinally
extensive spinal cord lesions were frequent, but short lesions occurred at least once in 44%. Fourty-one percent had a
history of simultaneous ON and myelitis. Clinical or radiological involvement of the brain, brainstem, or cerebellum was
present in 50%; extra-opticospinal symptoms included intractable nausea and vomiting and respiratory insufficiency (fatal
in one). CSF pleocytosis (partly neutrophilic) was present in 70%, oligoclonal bands in only 13%, and blood-CSF-barrier
dysfunction in 32%. Intravenous methylprednisolone (IVMP) and long-term immunosuppression were often effective;
however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups
after steroid withdrawal. Full recovery was achieved by plasma exchange in some cases, including after IVMP failure.
Breakthrough attacks under azathioprine were linked to the drug-specific latency period and a lack of cotreatment with
oral steroids. Methotrexate was effective in 5/6 patients. Interferon-beta was associated with ongoing or increasing
disease activity. Rituximab and ofatumumab were effective in some patients. However, treatment with rituximab was
followed by early relapses in several cases; end-of-dose relapses occurred 9-12 months after the first infusion. Coexisting
autoimmunity was rare (9%). Wingerchuk’s 2006 and 2015 criteria for NMO(SD) and Barkhof and McDonald criteria for
multiple sclerosis (MS) were met by 28%, 32%, 15%, 33%, respectively; MS had been suspected in 36%. Disease onset
or relapses were preceded by infection, vaccination, or pregnancy/delivery in several cases.
Conclusion: Our findings from a predominantly Caucasian cohort strongly argue against the concept of MOG-IgG
denoting a mild and usually monophasic variant of NMOSD. The predominantly relapsing and often severe disease
course and the short median time to second attack support the use of prophylactic long-term treatments in patients with
MOG-IgG-positive ON and/or myelitis.
Keywords: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG), Autoantibodies, Neuromyelitis optica spectrum
disorders (NMOSD), Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG), Optic neuritis, Transverse myelitis, Longitudinally
extensive transverse myelitis, Magnetic resonance imaging, Cerebrospinal fluid, Oligoclonal bands, Electrophysiology,
Evoked potentials, Treatment, Therapy, Methotrexate, Azathioprine, Rituximab, Ofatumumab, Interferon beta, Glatiramer
acetate, Natalizumab, Outcome, Pregnancy, Infections, Vaccination, Multiple sclerosis, Barkhof criteria, McDonald criteria,
Wingerchuk criteria 2006 and 2015, IPND criteria, International consensus diagnostic criteria for neuromyelitis optica
spectrum disorders
Background
The term ‘neuromyelitis optica’ (NMO) was coined in
1894 and has since been used to refer to the simultan-
eous or successive occurrence of optic nerve and spinal
cord inflammation [1]. In the majority of cases, the
syndrome is caused by autoantibodies to aquaporin-4,
the most common water channel in the central nervous
system (AQP4-IgG) [2–5]. However, 10-20% of patients
with NMO are negative for AQP4-IgG [6–9]. Recent
studies by us and others have demonstrated the presence
of IgG antibodies to myelin oligodendrocyte glycopro-
tein (MOG-IgG) in a subset of patients with NMO as
well as in patients with isolated ON or longitudinally ex-
tensive transverse myelitis (LETM), syndromes that are
often formes frustes of NMO [10–12].
Most studies to date have found MOG-IgG exclusively
in AQP4-IgG-negative patients [11–17]. Moreover, the
histopathology of brain and spinal cord lesions of MOG-
IgG-positive patients has been shown to differ from that
of AQP4-IgG-posititve patients [18–20]. Finally, evi-
dence from immunological studies suggests a direct
pathogenic role of MOG-IgG both in vitro and in vivo
[10, 21]. Accordingly, MOG-IgG-related NMO is now
considered by many as a disease entity in its own right,
immunopathogenetically distinct from its AQP4-IgG-
positive counterpart. However, the cohorts included in
previous clinical studies were relatively small (median 9
patients in [10–17, 22–24]) and the observation periods
often short (median 24 months in [11–13, 15–17, 23–26]).
Moreover, some previous studies did not, or not predom-
inantly, include Caucasian patients [12, 15, 26], which is
potentially important since genetic factors are thought to
play a role in NMO [27].
In the present study, we systematically evaluated the
clinical and paraclinical features of a large cohort of 50
almost exclusively Caucasian patients with MOG-IgG-
positive optic neuritis (ON) and/or LETM. We report
on (i) epidemiological features; (ii) clinical presentation
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at onset; (iii) disease course; (iv) time to second attack;
(v) type and frequency of clinical attacks; (vi) brain, optic
nerve, and spinal cord magnetic resonance imaging
(MRI) features; (vii) cerebrospinal fluid (CSF) findings;
(viii) electrophysiological features (VEP, SSEP); (ix) type
and frequency of coexisting autoimmunity; (x) type and
frequency of preceding infections; (xi) association with
neoplasms; (xii) association with pregnancy and delivery;
(xiii) treatment and outcome of acute attacks; (xiv) re-
sponse to long-term treatments; and (xv) the long-term
prognosis. In addition, we evaluated whether and how
many MOG-IgG-positive patients with ON and/or mye-
litis met Wingerchuk’s revised 2006 diagnostic criteria
for NMO [28], the new 2015 international diagnostic
consensus criteria for NMO spectrum disorders
(NMOSD) [29], Barkhof ’s MRI criteria for MS, and/or
McDonald’s clinicoradiological criteria for MS.
The present study forms part of a series of articles on
MOG-IgG in NMO and related disorders. In part 1, we
investigated the frequency and syndrome specificity of
MOG-IgG among patients with ON and/or LETM,
reported on MOG-IgG titers in the long-term course of
disease, and analyzed the origin of CSF MOG-IgG [30]. In
part 3, we describe in detail the clinical course and presen-
tation of a subgroup of patients with brainstem encephal-
itis and MOG-IgG-associated ON and/or LETM, a so far
under-recognized manifestation of MOG-related auto-
immunity [31]. Part 4 is dedicated to the visual system
in MOG-IgG-positive patients with ON and reports
findings from optical coherence tomography (OCT) in
this entity [32].
Methods
Clinical and paraclinical data of 50 MOG-IgG-positive
patients from 12 non-pediatric academic centers were
retrospectively evaluated; eight of the participating cen-
ters are members of the German Neuromyelitis optica
Study Group (NEMOS) [33–37]. MOG-IgG was de-
tected using an in-house cell-based assay (CBA) employ-
ing HEK293A cells transfected with full-length human
MOG as previously described [10] and confirmed by
means of a commercial fixed-cell based assay employing
HEK293 cells transfected with full-length human MOG
(Euroimmun, Lübeck, Germany) (see part 1 of this art-
icle series for details [30]). The study was approved by the
institutional review boards of the participating centers, and
patients gave written informed consent. Averages are given
as median and range or mean and standard deviation as in-
dicated. Fisher’s exact test was used to compare frequencies
between groups and the Mann-Whitney U test to compare
medians between groups. Due to the exploratory nature of
this study no Bonferroni correction was performed. P
values <0.05 were considered statistically significant.
Case reports
As reliable cell-based assays for the detection of MOG-
IgG have become available only recently, large and
comprehensive case series illustrating the broad and
heterogeneous spectrum of clinical manifestations, disease
courses, and radiological presentations are lacking so far.
We therefore decided to present, in addition to descriptive
statistical data, detailed reports on all cases evaluated in
order to draw for the first time a more vivid ‘real-life’ pic-
ture of this rare disorder than statistical analyses alone
could provide. Moreover, only detailed case descriptions
allow evaluation of treatment responses and outcomes in
a meaningful way in a retrospective setting. This is im-
portant, since randomized treatment trials in MOG-IgG-
positive ON or myelitis do not exist so far and will not be
performed in the near future due to the rarity of the con-
dition. The reports are to be found in the Appendix of this
paper and in the Case reports section in part 3 of this
article series [31].
Results
Epidemiological findings
Thirty-seven of the 50 MOG-IgG-positive patients were
female, corresponding to a sex ratio of 1:2.8 (m:f) (Fig. 1a).
Median age at onset was 31 years (35.5 years in patients
presenting with isolated ON [N = 32] and 28.5 years in the
remainder [N = 18]; p < 0.04) with a broad range of 6 to
70 years. 3 patients were > =60 years of age at onset, and 8
patients were under 18 at first attack (including 4 ≤
12 years) (Fig. 1b). Fourty-nine of the 50 patients (98%)
were of Caucasian and 1 of Asian descent. Symptoms had
started between Jul 1973 and Apr 2016. The mean obser-
vation period since disease onset was 75 ± 46.5 months
(range 1-507 months). In line with the fact that many
MOG-IgG-positive patients develop ON and myelitis only
successively, the mean observation period was longer in
patients with a history both of ON and of myelitis at last
follow-up (88.6 months; N = 22) than in patients with a
history of either ON but no myelitis or myelitis but not
ON (64.6 months; N = 28).
Disease course
Fourty of 50 MOG-IgG-positive patients (80%) had a
relapsing disease course. In the remaining 10 cases only
a single attack had occurred at last follow-up. The pro-
portion of patients with a monophasic course declined
with increasing observation time (Fig. 2, upper panel). If
only patients with a very long observation period
(≥8 years) are considered, 93% (13/14) had a recurrent
course (Fig. 2, lower panel). In line with this finding,
the median observation time was shorter in the ‘mono-
phasic’ than in the relapsing cases (26 vs. 52.5 months).
The proportion of patients with a relapsing disease
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Fig. 1 Sex ratio and age distribution. a Sex ratio in MOG-IgG-positive patients with ON and/or LETM compared with AQP4-IgG-positive ON and/or LETM
(the latter data are taken from ref. [34]). b Age distribution at disease onset in 50 MOG-IgG-positive patients with ON and/or myelitis
Fig. 2 Disease course in relation to observation time in 50 MOG-IgG-positive patients with ON and/or myelitis. Upper panel: Note the decrease in
the proportion of monophasic cases with increasing observation time; however, in some patients no relapse has occurred more than 10 years
after the initial attack. Lower panel: Note the shorter observation time in the ‘monophasic’ group (left lower panel) and the lower percentage of
non-relapsing cases among patients with a long observation period (≥8 years; right lower panel)
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course did not differ significantly between female (83.8%
[31/37]) and male (69.2% [9/13]) patients.
Symptoms developed acutely or subacutely in the vast
majority of cases; progressive deterioration of symptoms
was very rare (at least once in 3/46 or 7%) and reported
only in patients with myelitis.
Clinical presentation during acute attacks
Overall, 276 clinically apparent attacks in 50 patients were
documented. 205 attacks clinically affected the optic nerve,
73 the spinal cord, 20 the brainstem, 3 the cerebellum, and
9 the supratentorial brain. 44/50 (88%) patients developed
at least once acute ON, 28/50 (56%) at least once acute
myelitis, 12/50 (24%) at least once a brainstem attack, 2/50
(4%) acute cerebellitis, and 7/50 (14%) acute supratentorial
encephalitis (Fig. 3, upper panel).
At last follow-up, 26/50 (52%) patients had developed
at least two different clinical syndromes (i.e., combina-
tions of ON, myelitis, brainstem encephalitis, cerebellitis,
and/or supratentorial encephalitis), either simultaneously
or successively. Of these, 22 (84.6%) had experienced at-
tacks both of ON and of myelitis at last follow-up (cor-
responding to 44% [22/50] of the total cohort). Another
22 (44%) had a history of ON but not of myelitis (recur-
rent in 15 or 68.2%), and 6 (12%) had a history of mye-
litis but not ON (recurrent in 4; LETM in all) at last
follow-up (Fig. 3, lower panel).
Myelitis and ON had occurred simultaneously (with and
without additional brainstem or brain involvement) at least
once in 9/22 (40.9%) patients with a history of both ON
and myelitis at last follow-up (and in 18% or 9/50 in the
total cohort).
Overall, 16/50 (32%) patients presented at least once
with more than one syndrome during a single attack
(more than once in 10/16). While 15 attacks of myelitis
(without ON) in 11 patients were associated with clinical
signs and symptoms of simultaneous brain or brainstem
involvement, only 1 attack of ON (without myelitis)
in 1 patient had this association. Clinically inapparent
spinal cord, brain, or brainstem involvement was
detected in further patients by MRI (see Brain MRI
findings below and part 3 of this article series [31]
for details).
Symptoms associated with acute myelitis
Symptoms present at least once during attacks of myeli-
tis included tetraparesis in 8/29 (27.6%) patients, para-
paresis in 14/29 (48.3%), hemiparesis in 2/29 (6.9%),
and monoparesis in 2/29 (6.9%). Paresis was severe
(BMRC grades ≤2) at least once in 6/29 (20.7%)
patients. Attacks included at least once pain and
dysesthesia in 19/28 (67.9%) patients and were purely
sensory in 15/29 (51.7%). Sensory symptoms included
also Lhermitte’s sign. Bladder and/or bowel and/or
Fig. 3 Attack history at last follow-up. Upper panel: Frequencies of MOG-IgG-positive patients (N = 50) with a history of clinically manifest acute
optic neuritis (ON), myelitis (MY), brainstem encephalitis (BST), supratentorial encephalitis (BRAIN), and cerebellitis (CBLL) at last follow-up. Lower
panel: Frequencies of MOG-IgG patients with a history of optic neuritis (ON) and myelitis, ON but not myelitis, and myelitis (LETM in all cases) but
not ON, respectively, at last follow-up (n = 50)
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erectile dysfunction occurred at least once in 20/29
(69%) patients (Fig. 4).
Symptoms associated with acute ON
In 36/39 (92.3%) patients ON was associated with re-
duced high-contrast visual acuity (VA) as determined
using a Snellen chart. In one patient, low-contrast but not
high-contrast VA was reduced; in another patient with
hazy vision but normal high-contrast VA, low-contrast
VA was not tested. In a third patient, impaired color per-
ception and papilledema were the only clinical symptoms.
Most patients with ON reported retrobulbar pain and/
or pain on eye movement. Disturbed color vision includ-
ing color desaturation was reported in some patients,
but was not systematically examined in all patients.
Attack-related functional blindness (defined as VA ≤0.1)
in one or both eyes occurred at least once in 27/39
(69.2%) patients and VA ≤0.5 was present at least once in
33/39 (84.6%) during acute ON attacks (Fig. 5). Both eyes
were affected simultaneously (‘bilateral ON’) at least once
in 22/43 (51.2%) patients, and scotoma was noted at least
once in 23/35 (65.7%) with available data.
Other symptoms
Brainstem symptoms occurred in 12 MOG-IgG-positive
patients. A detailed analysis can be found in part 3 of
this article series [31]. Respiratory insufficiency due to
brainstem encephalitis (2 ×) or myelitis (1 ×) occurred
at least once in 3/48 (6.3%) patients with available data
(median observation time 50.5 months; range 1-507)
and was fatal in one of these two cases. Two patients
had clinical signs and symptoms indicating cerebellar
involvement. These included limb, gait, and stance
ataxia with or without accompanying dysarthria. Sensory
ataxia was noted in others.
Supratentorial brain lesions were symptomatic in 7
patients. These patients showed (sometimes severe)
headache, fatigue, psychomotor slowing, disorientation,
impaired consciousness/somnolence, hemihypesthesia,
meningism, and photophobia.
Of note, several further patients had brainstem, cerebel-
lar, and/or supratentorial brain lesions (see section Brain
MRI findings below and Appendix as well as part 3 of this
article series [31]) but no clinical symptoms attributable to
those lesions.
Presentation at onset
ON was clearly the most common manifestation at dis-
ease onset (present in 37/50 [74%] patients), followed
by myelitis (17/50 [34%]), brainstem encephalitis (4/50
[8%]) and symptoms attributable to brain (3/50 [6%])
or cerebellar lesions (1/50 [2%]). While in some patients
only one site was clinically affected, multiple manifesta-
tions were noted in others: thirty-two of 50 patients
(64%) initially presented with isolated ON; 9 (18%) with
isolated myelitis; 5 (10%) with simultaneous ON and
myelitis (additional brainstem involvement in 2); 1 (2%)
with simultaneous myelitis, rhombencephalitis, and supra-
tentorial encephalitis; 2 (4%) with myelitis and supraten-
torial encephalitis; and 1 (2%) with isolated brainstem
encephalitis (Fig. 6). Accordingly, clinical evidence for dis-
semination in space (here understood as involvement of
more than one of the following anatomical sites: optic
nerve, spinal cord, prosencephalon, brainstem, and/or
cerebellum) was present at onset in 8/50 (16%) patients
(compared to 16/50 (32%) if the entire observation period
is considered).
In the subgroup of patients with multiple manifestations
at follow-up (including NMO and any other combinations
of ON, myelitis, brainstem encephalitis, cerebellitis, and/or
supratentorial encephalitis) (N = 26), disease had started
with an isolated syndrome in 17 (65.4%) (isolated ON in
12 [46.2%] and isolated myelitis in 5 [36.4%]); with simul-
taneous ON and myelitis in 4 (15.4%); with simultaneous
Fig. 4 Symptoms present during attacks involving acute myelitis (N = 28 patients). BB = bladder and/or bowel.
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ON, myelitis, and brainstem encephalitis in 1 (3.8%); with
simultaneous myelitis, rhombencephalitis and supratentor-
ial encephalitis in 1 (3.8%); and with simultaneous myelitis
and supratentorial encephalitis in 2 (7.7%).
In the subgroup of patients meeting Wingerchuk’s
2006 criteria at last follow-up, 3/14 (21.4%) had simul-
taneous ON and myelitis at onset (exclusively or in com-
bination with brain, brainstem or cerebellar symptoms)
and 3/8 (37.5%) of those with ON at disease onset,
including 2 of the 3 cases with simultaneous ON and
myelitis – presented with bilateral ON.
The initial attack affected both eyes in 15/37 (40.5%)
of all patients with ON at onset and in 11/32 (34.4%) of
all patients with isolated ON at onset; overall, 15/50
(30%) patients had bilateral ON at onset (partly in com-
bination with other manifestations).
The first attack of myelitis was clinically characterized
by tetraparesis in 5 patients and by paraparesis in 6; in 5
patients, myelitis was associated with purely sensory
and/or autonomous symptoms at onset. In 2 patients,
respiratory dysfunction was among the presenting
symptoms.
Fig. 5 High-contrast visual acuity (VA) loss during acute ON (N = 39 patients). Blind: complete or functional blindness (VA ≤0.1) in one or both
eyes at least once; severe: VA ≤0.5; moderate: VA ≤0.75; mild: ≤1.0; none: high-contrast VA not affected, but low-contrast visual loss, color desaturation,
and/or scotoma present
Fig. 6 Presentation at onset. ON = optic neuritis, MY =myelitis, LETM = longitudinally extensive transverse myelitis, BST = brainstem encephalitis,
BRAIN = supratentorial encephalitis, CBLL = cerebellitis. § Includes two cases of simultaneous ON, myelitis and brainstem encephalitis at onset.
*Other presentations included simultaneous myelitis, rhombencephalitis and supratentorial encephalitis; simultaneous myelitis and supratentorial
encephalitis (2 ×); and isolated brainstem encephalitis. No data on spinal cord lesion length at disease onset were available from 1 patient
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Time to second attack
Among the MOG-IgG-positive patients with more than one
documented attack and available data, the median time be-
tween the first and the second attack was just 5 months
(range, 1-492; N= 38) (Fig. 7). There was no significant dif-
ference between patients with ON at onset (median of
6 months to next relapse; range 1-492) and patients with
myelitis at onset (median 4 months; range 1-23). The median
interval between first and second attack was slightly longer
among patients with full recovery from the first attack (n=
17) than in the remaining patients (6 vs. 3.5 months; p=n.s.).
Presentation at second attack
The most common manifestation (isolated [N = 22] or in
combination with other syndromes) at second attack was
ON (21/23 [91.3%], which was mostly unilateral (21/23
[91.3%]; no data in one case). Other presentations at sec-
ond attack included isolated myelitis (N = 12), isolated
supratentorial encephalitis (N = 1), myelitis with brain or
brainstem involvement (N = 2), and simultaneous ON and
myelitis with brain involvement.
The initial presentation had high predictive value for the
second attack: in 18 of 25 patients (72%) initially present-
ing with isolated ON, the second event was isolated ON
again (and in 19/25 or 76% patients, ON was among the
presenting manifestations); similarly, in 6/8 (75%) patients
with isolated myelitis the second event was also isolated
myelitis. Overall, at least one manifestation present at onset
(ON, myelitis, brainstem encephalitis, cerebellitis, supraten-
torial encephalitis) was present also at the second attack in
31/40 (78%) patients with a recurrent disease course.
Of note, both optic nerves were affected clinically early in
the disease course: in 6/10 (60%) patients with available
data who experienced a unilateral ON at disease onset and
ON at first relapse, the second attack affected the previously
unaffected eye (or both eyes). Overall, 21/34 (62%) patients
had a history of ON in both optic nerves (simultaneously or
subsequently) already after the second event.
Annualized relapse rate
If all patients with an observation time of ≥12 months are
considered, the median annualized relapse rate (ARR) was
0.83 (range 0.05-6.92) in the total group (n = 39) and 0.92
(range 0.05-6.92) among patients with a recurrent disease
course (n = 34). It was higher among female than among
male patients both in the total cohort (0.92 vs. 0.535; N =
29 and 10, respectively) and in the relapsing subgroup
(0.92 vs. 0.83; N = 27 and 7, respectively), but the differ-
ences were not statistically significant.
The median ARR was highest (1.17; range 0.05-4.2; N =
19) in relapsing patients with a history of both ON and
myelitis (n = 21), compared with 0.8 (range 0.5-6.92)
among patients with recurrent isolated ON but no myeli-
tis (n = 12) and 0.57 and 0.83 in the two only patients with
recurrent isolated LETM but no ON and an observation
time ≥12 months.
Brain MRI findings
Supratentorial MRI abnormalities were present at onset
in 17/48 (35.4%) MOG-IgG-positive patients and infra-
tentorial MRI lesions in 7/48 (14.6%). Supratentorial
MRI lesions at onset included periventricular lesions;
lesions in the corpus callosum (some of them confluent);
frontal, parietal, temporoparietal, and occipital deep
white matter lesions; subcortical or juxtacortical lesions
(including insular lesions); and, in one case, lesions in
the thalamus (pulvinar) and in the basal ganglia (puta-
men) (Fig. 8). In one patient leptomeningeal enhance-
ment was noted at onset (Fig. 8, panel d), and in one
both optic tracts were affected (Fig. 8, panel c).
Infratentorial lesions at onset included lesions in the
cerebral peduncles, the pons (incluing tegmentum),
Fig. 7 Time to first relapse in months. The red line indicates the median. The first relapse was defined as a new clinical attack occurring more
than 30 days after onset of the initial attack. No exact data was available in two cases
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medulla oblongata, cerebellar hemispheres, and cerebel-
lar peduncles (see part 3 of this series [31] for details).
Taking not only the first but all MRIs into account,
22/47 (46.8%) patients had supratentorial brain lesions
at least once; brainstem lesions occurred at least once in
14/48 (29.2%); and cerebellar lesions were noted at least
once in 6/48 (12.5%) (see part 3 of this series for details
[31]). Lesions affected the periventricular white matter,
deep white matter (in some cases large and confluent) and
corona radiata, sub- or juxtacortical white matter, corpus
callosum, thalamus (pulvinar), basal ganglia, cerebral
peduncles, pons (ventral, median, tegmentum), medulla
Fig. 8 Examples of brain lesions detected by MRI. a Sagittal FLAIR image showing callosal lesions as well as lesions extending from the
diencephalon to the pons (see case 8 in part 3 of this article series [31] for details). b Axial FLAIR MRI demonstrating lesions in the basal ganglia,
juxtacortically on the right side, und in the genu corporis callosi in the same patient. c Axial FLAIR image at the diencephalic level revealing
periependymal lesions (in addition to basal ganglia lesions). d Axial T1-weighted image with Gd demonstrating leptomeningeal enhancement
(see case 8 in part 3 [31]). E: Sagittal MRI showing a callosal lesion (see case 10 in the Appendix for details). f, g Axial T2-weighted (f) and coronal
FLAIR (g) images showing large, confluent T2 hyperintense lesions in the right temporal lobe (see case 7 in part 3 [31])
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oblongata (including the area postrema and the peria-
queductal gray), cerebellar hemispheres, and cerebellar
peduncles and were partly Gd-enhancing. Lesions were
found in the frontal, parietal, temporal, and occipital
lobes and in the insula. Taking the entire course of
disease into account, callosal lesions were present at
least once in 8/48 (16.7%) patients and periventricular
lesions in 12/47 (25.5%). Callosal lesions were
Fig. 9 Examples of optic nerve lesions detected by MRI. a, b T2-weighted (a) and T1-weighted (B, with Gd) MRI reveals swelling and Gd enhancement
of the left optic nerve. c, d (fat-suppressed): Longitudinal extensive Gd enhancement of the optic nerve (see cases 9 and 12 in part 3 [31] for details).
e Longitudinally extensive bilateral optic neuritis extending from the chiasm (E, black arrows) into the orbits, affecting the left more than the right optic
nerve. f-h Coronal T1-weighted MRIs display marked contrast enhancement of the intraorbital optic nerve as well as concurrent enhancement of the
perioptic nerve sheath, partly extending in the surrounding orbital fat, in patients with acute ON (cases 11, 29 and 19). I: Axial T1-weighted MRI shows
Gd enhancement along the right optic nerve in another patient (see case 13 in part 3 of this article series [31]). j, k Axial FLAIR imaging demonstrates
bilateral lesions in the optic tract (see case 8 in part 3 [31] for details) (j MRI at attack onset; k follow-up MRI 1 month later)
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longitudinally extensive (more than half the length of
the corpus callosum), as considered typical for AQP4-
IgG-positive NMOSD [29], in 1/8 (12.5%).
Optic nerve MRI findings
MRI signs of ON were present in at least 24/44 (54.5%) pa-
tients with available data, all of whom had a history of clin-
ical ON (Fig. 9). Intraorbital swelling of the optic nerve was
noted at least once in 13/21 (61.9%) patients, and contrast
enhancement in 20/21 (95.2%). A longitudinally extensive
optic nerve lesion (more than half the length of the nerve)
(n = 6) and/or involvement of the optic chiasm (n = 4), two
findings previously considered typical for AQP4-IgG-
positive NMO [29], were present during acute ON in 8/26
(30.8%) cases with available data. Signs of optic nerve atro-
phy were noted in at least 5 patients and involved the optic
chiasm in at least one of them. However, post-chiasmatic
parts of the optic pathway were also affected in individual
patients: as mentioned above, one patient had optic tract le-
sions, and occipital lobe white matter lesions were docu-
mented in four cases.
Of particular note, in 11/28 (39.3%) patients with
available data, perioptic contrast enhancement, i.e. gado-
linium enhancement within the nerve sheath and the
immediately surrounding orbital tissues, was present
during acute ON (Fig. 9). The remaining patients had
either no history of ON or no or no suitable post-contrast
orbital MRI was performed or retrospectively available for
re-analysis and the presence of absence of perioptic
enhancement was not mentioned in their MRI reports.
Spinal cord MRI findings
MRI signs of spinal cord inflammation were present in
29/44 (65.9%) patients with available data, including 27/
28 (96.4%) with a history of clinical myelitis (Fig. 10).
Spinal MRI was performed also in 16 patients without a
history of clinically apparent myelitis and showed a spinal
cord lesion extending over 2 segments in 2 of them.
In 20 out of the 28 (71.4%) patients with a history of
clinical myelitis and available data, two or more lesions
were present simultaneously (i.e., in the same MRI) at
least once.
Spinal cord lesions on MRI extending over three or more
vertebral segments (VS), i.e., so-called LETM lesions, were
documented in 21/29 (72.4%) patients at least once. LETM
lesions were present during the first attack in 11/17
(64.7%) patients initially presenting with acute myelits.
By contrast, in 8 patients exclusively short lesions (<3
VS), i.e., so-called non-longitudinally extensive transverse
myelitis (NETM) lesions, were documented over the en-
tire observation period. Of potential differential diagnostic
importance, spinal cord MRI showed one or more NETM
lesions but no LETM lesions at disease onset in 6/17
(35.3%) patients initially presenting with acute myelitis
(alone or in combination with other syndromes). If all
available MRIs are considered, MRI lesions extended over
Fig. 10 Examples of spinal cord MRI findings. a Sagittal T2-weighted spinal MRI performed at disease onset revealed a large longitudinal centrally located
lesion extending over the entire spinal cord as well as swelling of the cord. b Longitudinal extensive central spinal cord T2 lesion in another patient. c
T2-hyperintense lesions extending from the pontomedullary junction throughout the cervical cord to C5 in a third patient. The insets in A and C show axial
sections of the thoracic cord at lesion level
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fewer than three segments during acute attacks of myelitis
in 12/27 (44.4%) patients.
The median length of all documented LETM lesions
(n = 32) was 4 VS (range 3-20) and that of all docu-
mented NETM lesions (n = 44) was 1.5 VS (range 1-2).
If all spinal cord lesions with available data are consid-
ered (n = 76), i.e., both LETM and NETM lesions (in-
cluding NETM lesions present in addition to LETM
lesions in the same MRI), the median longitudinal exten-
sion was 2 VS (range 1-20). Finally, the median length of
the longest spinal cord lesion (LETM or NETM) ever
observed in each patient was 5 VS (range, 1-20; N = 27)
if all patients with available MRI data were considered
and 5 (range, 1-20; N = 26) if only patients with clinical
evidence for myelitis were considered.
Swelling of the spinal cord was noted at least once in
19/27 (70.4%) patients and contrast enhancement in 19/
28 (67.9%). Signs of necrosis of the spinal cord were
noted in 0/23 (0%) patients with available data.
Spinal cord lesions were located in the cervical spinal
cord at least once in 23/28 (82.1%) patients and in the
thoracic spinal cord at least once in 21/28 (75%). Lum-
bar and conus lesions were documented only in 3/27
(11.1%) and 3/27 (11.1%) patients, respectively. Taking
all available spinal cord MRIs into account, cervical le-
sions were present in 44/81 (54.3%) MRIs, thoracic le-
sions in 31/81 (38.3%), lumbar lesions in 4/81 (4.9%),
and the conus was affected in 3/81 (3.7%). However, as
a limitation, not all MRIs performed showed the entire
spinal cord, and spinal cord MRI data were absent for
18 myelitis attacks in 8 patients.
Information on intramedullary lesion location was
available for 34 lesions in 20 MOG-IgG-positive patients.
Lesions were located predominantly in the central por-
tion of the spinal cord in 17 MRIs and predominantly in
the peripheral portion in another 17 MRIs.
The spinal cord MRI was normal during 2 attacks; in
both cases, symptoms were purely sensory (paresthesia
and hyp- and dysesthesia, respectively). Of note, a total
of five asymptomatic spinal cord lesions were noted in
two patients (in addition to brainstem lesions in one)
with a history of ON but no clinical evidence of myelitis
over the course of disease.
Evaluation of Barkhof’s and Paty’s MRI criteria for MS
Seven of 46 (15.2%) MOG-IgG-positive patients with a
history of myelitis and/or ON and 7/26 (26.9%) of those
with brain lesions met Barkhof ’s MRI criteria for MS at
least once [38]. However, at least 2 of the 7 patients
meeting Barkhof ’s criteria also had one or more
NMOSD-typical lesions at least once.
The revised 2006 diagnostic criteria for NMO [28]
required a brain MRI at disease onset that does not meet
Paty’s MRI criteria for MS [39] if either no LETM lesion is
present or NMO-IgG is negative. Accordingly, Paty’s
criteria were evaluated only at disease onset. In the present
cohort, the initial MRI of 12 out of 48 (25%) MOG-IgG-
positive patients with available data met Paty’s criteria.
Intrathecal IgG synthesis
Data on CSF-restricted oligoclonal IgG bands (OCB)
were available from 45/50 (90%) MOG-IgG-positive pa-
tients. Pattern 2 or 3 OCB [40] indicative of intrathecal
IgG synthesis were positive at least once only in 6/45
(13.3%). A second lumbar puncture was performed in 2
out of the 6 OCB-positive patients, in both of whom
OCB remained positive.
Patients with classical MS display a polyspecific, intra-
thecal humoral immune response to neurotropic viruses
such as measles, rubella, and varicella zoster virus (the
so-called MRZ reaction, MRZR) [41–44]. MRZR was
tested in 11 MOG-IgG-positive patients (2 x ON +mye-
litis; 1 x ON +myelitis + brainstem encephalitis; 1 x mye-
litis + brainstem encephalitis; 3 x LETM; 5 x ON) and
was negative in all of them.
CSF white cell counts
White cell counts (WCC) in the CSF were documented
at least once in 46 MOG-IgG-positive patients and were
elevated (>5/μl) in 32 (69.6%). In those patients with
pleocytosis, WCC ranged between 6 and 306 cells/μl
(median 33; quartile range 13-125). WCC ≥100 cell/μl
were present at least once in 9/32 (28.1%) patients.
Neutrophil granulocytes were present at least once in 9/
14 (64.3%) patients with pleocytosis and available data
(median 22% of all white cells; range 3-69%).
Blood-CSF barrier function
An increased albumin CSF/serum ratio (QAlb) reflects a
disturbed blood-CSF barrier (BCSFB) function caused by
structural damage and/or a reduced CSF flow rate [45].
QAlb was determined in 37 MOG-IgG-positive patients
and was elevated in 12 (32.4%). Blood-CSF barrier dys-
function was present both among patients with a history
of isolated ON (2/15; 13.3%) and, more frequently, in
patients with a history of spinal cord and/or brain/brain-
stem involvement (10/21; 47.6%).
Visual evoked potentials
Data on visual evoked potentials (VEP) were available
from 47 MOG-IgG-positive patients. A delayed P100 la-
tency was noted at least once in 34 (72.3%); in another 6
(12.8%) patients latencies could not be determined since
potentials were lost due to severe optic nerve damage.
Only 41 (78.7%) of the 47 patients examined had a
history of clinically manifest ON; in 31 of these 41
patients (75.6%) P100 latency was delayed, and in 6 fur-
ther patients (14.6%) latencies could not be determined.
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The remaining 6 patients had a history of myelitis
(LETM in all cases) but no history of clinically manifest
ON. 3 of those 6 had delayed P100 latencies in at least
one eye, indicating that subclinical optic nerve damage
might be relatively frequent in MOG-IgG-positive pa-
tients with myelitis.
In 23/41 (56.1%) patients, all of whom had a history
of clinical ON, VEP amplitudes were reduced (n = 16) or
lost (n = 7) at least once. In all but one patient with re-
duced amplitudes, P100 latencies were also delayed at
some point in time, but not vice versa.
Somatosensory evoked potentials
Data on somatosensory evoked potentials (SSEP) were
available from 39 MOG-IgG-positive patients, including 24
with a history of clinically manifest myelitis. SSEP were de-
layed, reduced in amplitude, or lost in 19/39 (46.2%), in-
cluding in 16/24 (66.7%) with a history of clinical myelitis
and available data. Of note, 3 patients with no clinical his-
tory of myelitis had SSEP abnormalities suggestive of sub-
clinical spinal cord damage (none of them displayed
unequivocal spinal cord MRI abnormalities).
Ophthalmoscopic findings
Fundoscopy revealed uni- or bilateral papillitis or papille-
dema in at least 15 patients with acute ON, suggesting in-
flammation of the anterior part of the optic nerve. The true
prevalence of papillitis could be higher, however, since oph-
thalmoscopic data were not available from all patients. In
case 6 (see Appendix), papilledema was described as
marked (3 dpt) at first ON and as mild at second and third
ON, while later on the optic disk was described as atrophic
and pale. Optic atrophy as detected by fundoscopy was
noted at last follow-up in 13/22 (59.1%) patients with avail-
able data.
Evaluation of the 2010 McDonald criteria for MS
If MOG-IgG seropositivity is not considered to constitute
per se a “better explanation” [46], i.e., based solely on clini-
coradiological criteria, 15/46 or 33% of the patients with
available data met the most current diagnostic criteria for
MS [46] (Table 1). Taking only MOG-IgG-positive patients
with a history of both ON and myelitis into account, 10/20
or 50% with available data fulfilled those criteria, compared
with 7/31 or 23% with a history of ON but not myelitis or
of myelitis but not ON at last follow-up. If only patients
with a relapsing disease course are taken into account, 44%
(15/34) met the 2010 McDonald criteria.
Evaluation of the 2006 criteria for NMO
63.6% (14/22) of all MOG-IgG-positive patients with a his-
tory of both ON and myelitis met Wingerchuk’s 2006 re-
vised diagnostic criteria for NMO [28] (Table 1). Of the 8
patients with ON and myelitis who did not meet
Wingerchuk’s 2006 criteria, two had an LETM lesion but
the first brain MRI met Paty’s criteria for MS; five did not
meet Paty’s criteria at onset but spinal cord lesions extended
over fewer than three vertebral segments; and one met
Paty’s criteria at onset and had no LETM lesion.
Twenty eight patients had a history of ON but not myeli-
tis or a history of myelitis but not ON (both with and with-
out brain involvement) and did therefore not meet the 2006
diagnostic criteria. Taking the total cohort into account,
28% (14/50) of all patients met the 2006 criteria for NMO.
Seven out of 43 (16%) patients with available data fulfilled
both the clinicoradiological 2006 criteria for NMO [28] and
the clinicoradiological 2010 McDonald criteria for MS [46].
Evaluation of the 2015 criteria for NMOSD
On the understanding that MOG-IgG seropositivity does
not per se constitute an “alternative diagnosis”, i.e., based
solely on clinical and radiological criteria, 16/50 (32%) pa-
tients met the 2015 international consensus criteria for
NMOSD [29] (Table 1). Of those, 15 had a history of both
ON and myelitis and 1 a history of ON but not of myelitis
(this patient fulfilled the criteria despite the lack of myelitis
due to the presence of brainstem encephalitis with perie-
pendymal lesions around the fourth ventricle and of symp-
tomatic, extensive white matter lesions); none had a history
of myelitis but not of ON. Of those patients who met the
2006 criteria, 12 (85.7%) also met the 2015 criteria. Con-
versely, 12 (75%) of those who met the 2015 criteria also
met the 2006 criteria. 8 out of 43 (19%) patients with avail-
able data fulfilled both the clinicoradiological 2015 criteria
for NMOSD and the clinicoradiological 2010 McDonald
Table 1 Patient numbers and diagnoses
Diagnostic categories N (%)
History of ON and/or MY 50/50 (100%)
History of ON 44/50 (88%)
History of myelitis 28/50 (56%)
Meeting Wingerchuk’s 2006 criteria for NMOa 14/50 (28%)
Meeting 2015 consensus criteria for NMOSDb 16/50 (32%)
Meeting 2010 McDonald criteria for MSc 15/46 (33%)
History of ON and of myelitis 22/50 (44%)
Meeting Wingerchuk’s 2006 criteria for NMOa 14/22 (63.6%)
Meeting 2015 consensus criteria for NMOSDb 15/22 (68.2%)
History of ON but not of myelitis 22 (44%)
Meeting Wingerchuk’s 2006 criteria for NMOa 0/22 (0%)
Meeting 2015 consensus criteria for NMOSDb 1/22 (4.5%)
History of myelitis but not of ON 6/50 (12%)
Meeting Wingerchuk’s 2006 criteria for NMOa 0/6 (0%)
Meeting 2015 consensus criteria for NMOSDb 0/6 (0%)
MS multiple sclerosis, NMO neuromyelitis optica, NMOSD NMO spectrum
disorder, ON optic neuritis. asee ref. [28], bsee ref. [29], csee ref. [46]
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criteria for MS. If only patients with a relapsing course of
disease are considered, 16/40 (40%) met Wingerchuk’s
2015 criteria.
Previous diagnoses
As reliable tests for MOG-IgG became available only rela-
tively recently, most of the patients initially received diag-
noses other than MOG-IgG-positive encephalomyelitis
(EM). In 16/45 (35.6%) patients with available data, a diag-
nosis of MS was suspected at least once. Other suspected
diagnoses included acute disseminated EM (ADEM), multi-
phasic disseminated EM, AQP4-IgG-negative NMO
according to Wingerchuk’s 2006 criteria [28], AQP4-IgG-
negative NMOSD according to the 2015 international diag-
nostic consensus criteria [29], viral encephalitis, bacterial
encephalitis, paraneoplastic encephalitis, isolated vasculitis
of the CNS, chronic relapsing inflammatory optic
neuropathy (CRION), CNS lymphoma, sarcoidosis,
spinal stenosis, “spinal tumor of unknown dignity”,
suspected spinal ischemia, para- or postinfectious ON,
and myelitis; some patients were diagnosed with ON,
rON, (longitudinally extensive transverse) myelitis,
brainstem encephalitis or EM “of unknown origin”.
Coexisting autoimmunity
Coexisting autoantibodies were present in 19/45 (42.2%)
MOG-IgG-positive patients. These included antinuclear
antibodies (ANA) in at least 14 patients and cardiolipin
antibodies or phospholipid/glycoprotein beta-2 antibodies
(2 ×), anti-tissue transglutaminase IgA (1 ×), rheuma-
toid factor (1 ×), anti-thyroid peroxidase (2 ×), anti-
thyreoglobulin (1 ×), anti-thyroid-simulating hormone
receptor (1 ×), perinuclear anti-neutrophil cytoplasmic
antibodies (ANCA) (1×). None of the 50 patients was
positive for AQP4-IgG [30].
Concomitant autoimmune disorders were present only
in 4/47 (8.5%) patients and included rheumatoid arth-
ritis (RA) (2 ×), Hashimoto thyroiditis (1 ×), Grave’s dis-
ease (1 ×). A further patients had atopic dermatitis and
asthma bronchiale.
Preceding infections
Disease onset was preceded by infection in at least 11 pa-
tients. Diagnoses included common cold, sore throat, ton-
sillitis, sinusitis, bronchitis, “respiratory infection”, “feverish
infection”, and, in one case, a gastrointestinal infection with
positive Yersinia serology (species not determined).
Taking not only the first but all attacks into account,
attacks were preceded by infection at least once in at
least 15/37 (40.5%) patients; the infections included, in
addition to those already mentioned above, “mycoplasma
pneumonia,” one case each of a non-specified “respira-
tory” or “bronchopulmonary” infection, a “feverish com-
mon cold”, “fever and fatigue”, and a non-specified
“feverish infection”. In at least one patient, both the first
and the second attack were preceded by infection.
One further patient reported a history of two episodes of
“borreliosis with meningitis” 20 and 19 years before onset.
Preceding vaccinations
Disease onset was preceded by revaccination against diph-
theria, tetanus, pertussis, polio, and influenza 2 weeks prior
to symptom onset in one patient (for details of this case see
part 3 of this series [31]), and by vaccination against diph-
theria, tetanus, and pertussis 13 days prior to symptom
onset in a second case; the latter patient developed fever 2 -
3 days before symptoms started. Both patients (1 ×male,
1 × female) were vaccinated at adult age (19 and 47 years)
and both developed recurrent disease. While the first patient
experienced seven relapses involving the the optic nerves
(4 ×), spinal cord (5 ×), brain (2 ×), and brainstem (1 ×)
within 20 months, which fully responded to IVMP or com-
bined IVMP and plasma exchange (PEX), the second patient
developed three attacks (2 ×ON, 1 ×myelitis and ON)
within 6 months, which only partially responded to IVMP,
PEX and IA and resulted in an EDSS of 8 at discharge; two
of the attacks occurred despite treatment with rituximab.
Pregnancy-associated attacks
Seventeen percent (5/30) of all female patients aged ≥15 years
at last follow-up experienced at least one attack of ON or
myelitis during pregnancy or post partum. This corre-
sponded to 50% (5/10) of all patients with a documented
pregnancy (no data in 9) and, importantly, included all 5/5
women of reproductive age with available data who were
pregnant shortly before (i.e., within the last 18 months), at,
or after disease onset. Of a total of seven attacks, three had
occurred during pregnancy and four post partum. These in-
cluded the first attack ever in 3 patients: Disease started with
simultaneous ON and LETM and accompanying brainstem
and brain lesions occurring just 6 weeks after the delivery of
the first child in one case; with an attack of unilateral ON
3 months post partum and during breast-feeding in a second
patient; and with an attack of bilateral ON 8 months after
delivery and while still breast-feeding in a third (as a limita-
tion, however, ON was also preceded by a common cold
with mild fever in this last case). In a fourth patient, an attack
of LETM occurred during week 6 of pregnancy and an attack
of bilateral ON a few weeks after delivery; however, the dis-
ease had started 8 years earlier in this patient and several
ON attacks had occurred in the meanwhile. A fifth patient
experienced at least two attacks of ON during pregnancy,
which responded well to IVMP; disease had started 2 years
before. While 3 patients had a relapsing course, 2 have not
developed further attacks so far, although the follow-up time
is short (6 and 3 months, respectively). Overall, 7/23 attacks
in the 3 relapsing patients were associated with pregnancy or
delivery, while the majority of attacks were not.
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Tumor associations
In a single patient presenting with post-infectious whole-
spine myelitis and severe brainstem and brain inflamma-
tion, a mature cystic ovarian teratoma had been removed
2 months before onset of the neurological symptoms, but
no signs of malignancy had been found; NMDAR anti-
bodies were negative. In the same patient, a ganglioneur-
oma was found and resected at a later date. MOG-IgG
were not associated with malign tumors also in all other pa-
tients studied.
Treatments for acute attacks
Acute attacks were treated with high-dose IVMP at least
once in 47/48 (97.9%) MOG-IgG-positive patients, with
PEX at least once in 19/48 (39.6%), and with immunoad-
sorption (IA) in two. Other treatments included oral ste-
roids or dexamethasone i.v. followed by oral steroids in
single patients as well as acyclovir and/or antibiotics for
pragmatic treatment of initially suspected CNS infection.
Overall, 136 documented attacks were treated with IVMP,
15 with PEX, and 25 with both IVMP and PEX or – in five
of them - IA; 18 were not treated at all. PEX or IA were
used to treat 20 ON attacks, 16 myelitis attacks (with or
without brain and/or brainstem and/or cerebellum involve-
ment), 3 attack of simultaneous ON and myelitis (with or
without additional clinical brain involvement), and 1 pure
brainstem attack.
Overall outcome of acute attacks
Outcome data were available for 134 ON attacks in 39
MOG-IgG-positive patients and for 46 myelitis attacks in
23 MOG-IgG-positive patients. Complete or almost
complete recovery from acute ON was noted after 70
(52.2%) ON attacks, partial recovery after 54 (40.3%),
and no or almost no recovery after 10 (Fig. 11b). Complete
or almost complete recovery from acute myelitis was
noted in 16 (34.8%) attacks, partial recovery in 30
(65.2%), and no or almost no recovery in none (Fig. 11a).
At last follow-up, 38/48 (79.2%) patients had experi-
enced complete or almost complete recovery from at
least one attack. In contrast, 22/48 (45.8%) had experi-
enced at least one attack that was followed by no or
almost no recovery. While 62.2% (28/45) of the pa-
tients’ initial attacks remitted completely or almost
Fig. 11 Outcome after acute attacks in MOG-IgG-positive patients compared with a previously published AQP4-IgG-positive cohort. a Outcome
after acute myelitis in MOG-IgG-positive (46 evaluable attacks) and in AQP4-IgG-positive patients (298 evaluable attacks [34]). b Outcome after
acute ON in MOG-IgG-positive (134 evaluable attacks) and in AQP4-IgG-positive patients (205 evaluable attacks; see ref. [34]). Note that ‘complete
recovery’ includes ‘almost complete recovery’ in the left graph (no such distinction was made in the AQP4-IgG-positive cohort)
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completely, the proportion was lower for all subsequent
attacks (40.6% or 69/170) and dropped to 26.4% or
19/72 after the fifth relapse.
Outcome of attacks treated with IVMP
Outcome data were available for 122 attacks treated with
IVMP but not PEX (including attacks of ON; myelitis;
brainstem encephalitis; cerebellitis; supratentorial enceph-
alitis; simultaneous ON and myelitis; simultaneous ON,
myelitis, and brainstem encephalitis; simultaneous ON,
myelitis, and supratentorial encephalitis; simultaneous
myelitis and brainstem encephalitis; simultaneous myelitis
and supratentorial encephalitis; and simultaneous myelitis,
brainstem, and brain inflammation). In 61 (50%) of those
relapses, IVMP treatment was followed by complete or
almost complete recovery, in 54 (44.3%) by partial re-
covery, and in 7 (5.7%) by no or almost no recovery.
Of particular note, symptoms flared up after withdrawal
or tapering of steroids at least once in 21/47 (44.7%) pa-
tients (see Appendix and Discussion for details). To control
symptoms, IVMP was combined with or escalated to PEX
or IA in 17/48 (35.4%) patients at least once and for 9.1%
(25/276) of all documented attacks. If those attacks that
were subsequently treated with PEX are also taken into ac-
count and on the understanding that the use of PEX after
IVMP implies partial or full IVMP failure, 86/147 (58.5%)
attacks initially treated with IVMP responded only partially
or not at all to IVMP, while IVMP was followed by
complete or almost complete recovery in 41.5%.
Outcome of attacks treated with PEX or IA
Outcome data were available for 40 attacks treated ei-
ther with PEX/IA alone or with both IVMP and PEX/IA;
IA instead of PEX was used to treat five of those attacks.
Stand-alone PEX/IA was used for treating attacks (N =
15) of ON and/or myelitis with and without brain or
brainstem involvement and attacks of isolated brainstem
encephalitis. The median number of PEX/IA cycles used
per attack was 5 (range, 3-11). In 3 (20%) of those 15 at-
tacks, PEX treatment was followed by complete or almost
complete recovery, in 11 (73.3%) by partial recovery, and
in 1 by no or almost no recovery.
In addition, 25 attacks of ON and/or myelitis (with and
without brain and/or brainstem involvement) were treated
with both IVMP and, subsequently, PEX/IA. In 10 (40%)
of these attacks, PEX/IA treatment was followed by
complete or almost complete recovery, in 14 (56%) by
partial recovery, and in 1 by no or almost no recovery.
If all attacks treated with PEX/IA (with or without
IVMP) are considered, PEX/IA treatment was followed
by complete or almost complete recovery in 13 (32.5%)
attacks, by partial recovery in 25 (62.5%), and in 2 (5%)
by no or almost no recovery.
IA was used instead of PEX for two attacks of ON in
case 11. While treatment with four courses of IA was
followed by almost complete recovery from an ON attack
that had responded only transiently to a first IVMP cycle
(and not at all to a second one) and by a relapse-free
period of 3 years, the next ON attack responded only par-
tially to IVMP and four courses of IA. The reason for the
differential response to IA during those two relapses is un-
known, but, as with PEX, differences in antibody titers as
well as timing issues might have played a role. In case 28,
IA resulted only in partial recovery when used after IVMP
to treat three attacks of isolated myelitis, simultaneous
ON and myelitis, and of isolated ON, respectively.
Outcome of untreated attacks
Only 14 attacks in 11 patients were not treated with ste-
roids or PEX/IA. Among those attacks, no or almost no
recovery was noted in 2 cases (acute ON and brainstem
encephalitis in one patient, ON in a second), one of
which was fatal, partial recovery in 3 (acute ON in all), and
full or almost full recovery in 9 (acute ON in 7, acute en-
cephalitis/brainstem encephalitis in 2 ). The reasons for not
treating patients for acute attacks were not specified in all
cases. IVMP treatment was declined by at least two patients
once each (no recovery in one and full recovery in the other
one), and a decision in favor of palliative care had been pre-
viously made in another patient; in at least one case, ON
was considered mild and therefore left untreated.
Long-term treatments
Long-term immunosuppressive (IS) or immunomodula-
tory (IM) treatments were used at least once in 35/49
(71.4%) patients and included azathioprine (AZA) in 18,
methotrexate (MTX) in 8, rituximab in 16, glatiramer
acetate (GLAT) in 5, interferon-beta (IFN-beta) in 4,
natalizumab (NAT) in 3, ofatumumab in 1, intravenous
immunoglobulins (IVIG) in 1, mitoxantrone in 2, ciclos-
porin in 1, mycophenolate mofetil in 1, and oral steroids
in 5; 14 patients (including 8 with a so far monophasic
disease course) never received any IS/IM treatment.
Breakthrough attacks were noted in 21/31 (67.7%)
patients treated with IS/IM at least once.
Response to AZA treatment
Data on acute attacks during AZA therapy were available
from 17/18 patients treated. The median treatment period
was 10 months (range 2-101). Of these 17 patients, 14
(82.4%) experienced at least one attack under treatment
with AZA. In total, 34 attacks occurred under AZA over a
cumulative treatment period of 412 months (cumulative
ARR 0.99) with a median of 1 attack/patient (range 0-6) in
the total AZA group and of 1.5 attacks/patients (range 1-6)
in those who had breakthrough relapses.
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Of particular note, 14 of the 34 attacks (41%) took place
during the first 6 months, i.e., during the drug-specific latency
period.Of these, 11 attacksdevelopedduring the first 3months
and only 3 during months 4-6. If all patients are taken into ac-
count, the median of all individual ARRs was 2 during the 6-
monthAZA latency period and 0.92 after the latency period.
Cotreatment with oral steroids or, in a single case, regular
PEX was administered only in 9/23 (39.1%) patients (no
data in 2), either for 3 or for 6 months or for the entire
treatment period. Importantly, most attacks (12/14) ob-
served during the AZA latency period occurred in patients
who were not cotreated. Relapses occurred in only 1 of 14
cotreated patients during the latency period, but in 6/9
patients who were not cotreated. Similarly, 4/5 patients
who developed relapses after the latency period were not
cotreated, and 14/17 attacks occurring during that period
affected non-cotreated patients. Taking the total treatment
period into account, 10/12 patients with relapses under
AZA were not cotreated at the time of the attack and
26/31 attacks occurred in non-cotreated patients.
Response to MTX treatment
Data on acute attacks before and during MTX therapy were
available from six patients. In case 13 (see Appendix for
case reports), a single (though severe and non-remitting)
relapse occurred under MTX within 134 months compared
with 3 attacks in an 11-month period including 9 months
of combined treatment with AZA and oral steroids. As a
possible limitation, it remains unclear whether further at-
tacks in the affected right eye went unrecognized due to
the pre-existing severe visual deficit. Patient 3 experienced
two attacks (both with complete recovery) within a period of
5.5 years of MTX treatment. Of note, however, this included
the patient’s first attack ever, which occurred under active
MTX treatment for pre-existing RA. MTX was used as
treatment for RA also in patient 6 described in part 3 of this
article series [31]; in that patient, temporary discontinuation
of MTX after 5 years due to severe infection was followed
by the first relapse for 40 years. MTX was continued and no
further attack occurred over the following 12 months. Simi-
larly, patient 12 in part 3 of this series [31] suffered no at-
tacks during 21 months of MTX treatment, although, three
attacks had occurred within 7 months prior to commence-
ment of MTX. Finally, combined treatment with MTX and
oral steroids (plus ciclosporin A during the initial 7 months)
resulted in disease stabilization in case 6, with only two re-
lapses (with only partial recovery though) in almost
7 years; by contrast, 14 attacks had occurred in the
preceding 5 years in this patient (including during
treatment with IFN-beta, GLAT, AZA, or rituximab).
Overall, 5 attacks took place in 22.5 years in these
patients under treatment with MTX. This corresponds to
a cumulative ARR of 0.22, which is lower than the
cumulative ARR of 0.95 found among all patients (n = 34)
with a relapsing disease course. Patient 1, in whom three
breakthrough attacks occurred within 8 months of MTX
therapy, was the only patient with apparent MTX failure.
Response to IFN-beta treatment
No decrease in relapse rate was observed under treat-
ment with various IFN-beta preparations, which were
given for suspected MS. In case 6, commencement of
therapy with i.m. IFN-beta-1a (Avonex®) was followed by
two ON relapses 1 and 4 months later. Similarly, s.c.
IFN-beta-1a (Rebif®) was followed by an ON relapse less
than 2 months after treatment was started. Finally, treat-
ment with s.c. IFN-beta-1b (Betaferon®) was associated
with another ON relapse after 2 months. Overall, four
relapses occurred within around 16 months of IFN-beta
treatment (ARR 3.0). This is in strong contrast to just
two ON relapses within 71 months under therapy with
MTX and oral steroids in that patient (ARR 0.33). Of
interest, both IFN-beta-1a and -1b led to leukopenia. In
another patient (see case 5 in part 3 of this article series
[31] for details), further relapses occurred and marked
disease exacerbation on MRI was noted after the initiation
of i.m. IFN-beta-1a treatment, with new spinal and brain-
stem lesions. In a third patient (case 12), two relapses oc-
curred within 11 months and led to discontinuation of s.c.
IFN-beta-1a therapy. A fourth patient experienced an at-
tack of mild ON and myelitis after 8 months of IFN-beta
(Rebif®) therapy. When the same patient was again treated
with IFN-beta 5 years later (now with Avonex®), an attack
of severe unilateral ON occurred two months after treat-
ment initiation and an attack of ON in the opposite eye
with simultaneous myelitis after a further 2 months. In
total, she experienced three attacks during a total IFN-
beta treatment period of 19 months.
Response to GLAT treatment
Five patients were treated with GLAT for suspected MS.
In case 6, no relapse occurred over a period of 6 months;
by contrast, four relapses had occurred under IFN-beta
over a period of 16 months in the same patient. However,
considering the GLAT-specific latency period of 3-6
months observed in MS it remains uncertain whether that
decline in relapse rate was due to GLAT treatment or to
discontinuation of (potentially disease-exacerbating) IFN-
beta treatment. GLAT treatment had to be stopped due to
leukopenia in that patient. In case 8, no relapses occurred
over a period of 36 months on therapy with GLAT and re-
mission of spinal cord lesions was detected by MRI. How-
ever, this patient had previously experienced a relapse-free
interval of more than 5 years, rendering it uncertain also
in this case whether GLAT was effective. A third patient
(see case 1 in part 3 of this article series [31] for details)
was relapse-free for almost a year under GLAT, but
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experienced two relapses (1 x ON, 1 x myelitis) 11 and
13 months after initiation of therapy, leading to discontinu-
ation of GLAT. Previously, one to two relapses per year had
occurred over a period of around 6 years, and three relapses
within the last 10 months prior to GLAT. A fourth patient
(case 14 in part 3 [31]) experienced three ON attacks dur-
ing 8 months of GLAT treatment; moreover, a further re-
lapse of severe ON leading to transient unilateral blindness
occurred a few weeks after GLAT therapy was discontin-
ued. In a further patient (case 13 in part 3 [31]), two attacks
occurred during 7 months of treatment with GLAT (3 and
7 months after the first injection). When treated a second
time with GLAT more than 3 years later, she experienced a
protracted attack of myelitis with paresis, impaired coordin-
ation, and impaired ambulation 1 months after commence-
ment of therapy (and thus during the drug’s latency period),
which lasted over 2 months and required a total of three
cycles of high-dose IVMP therapy.
Response to NAT treatment
Three patients were treated with NAT for suspected MS.
In one of them (see case 1 in [31]), two infusions of NAT
were followed by three relapses by 2, 3 and 5 months,
which only partially responded to PEX. Treatment with
NAT was not continued after the second infusion due to
recurrent headache. In the second patient (see case 5 in
part 3 [31]) an attack of brainstem encephalitis occurred
and MRI showed a new LETM lesion 9 months after com-
mencement of NAT therapy. The third patient (case 13 in
part 3 [31]) experienced two myelitis attacks 1 and
4 months after initiation of NAT treatment, followed by a
relapse-free interval of 21 months. When NAT was re-
initiated 11 months later, she developed two further attacks
of myelitis after 4 and 5 months, followed by a relapse-free
interval of 9 months; treatment was discontinued due to
John Cunningham virus (JCV) seroconversion. In total, four
attacks occurred during 29 months of NAT treatment.
Response to rituximab and ofatumumab
Of 16 patients treated with rituximab at least once, ob-
servation periods under rituximab therapy were suffi-
ciently long to allow meaningful analyses of the drug’s
efficacy only in 9 patients.
Treatment with rituximab was followed by a decline in
relapse rate in 3/9: In one patient (see case 18 in the
Appendix), no relapse occurred in 12 months under rituxi-
mab compared with four relapses of ON within 6 months
beforehand. In another patient (see case 7 in part 3 of this
series [31]) one minor relapse with spontaneous remission
took place in 28 months, compared with three attacks
within the previous 4 months). Finally, in case 12, no re-
lapses occurred during 8 months of rituximab treatment
compared with three relapses in the preceding 14 months
(two of which, however, took place under treatment with
IFN-beta, which was reported to cause disease exacerbation
in NMO and which was associated with ongoing or in-
creasing disease activity also in our patients).
Of note, in the other six patients one or more attacks were
noted during therapy with rituximab, most of which occurred
shortly after rituximab infusion. This is reminiscent of early at-
tacks observed in AQP4-IgG-positive NMO patients treated
with rituximab. Two relapses of ON occurred 3 and 7 weeks
after the first rituximab infusion (2 × 1000 mg i.v., days 1 and
15) in case 6 (see Appendix). Similarly, patient 1 in part 3 of
this series [31] developed severe clinical and radiological de-
terioration 4 weeks after the first and 2 weeks after the second
infusion of rituximab. The latter patient had been treated with
PEX 1 month before rituximab was started, indicating that
even pretreatment with PEXmay not be sufficient in all cases
to prevent the risk of rituximab-related attacks. A further pa-
tient developed two relapses of ON one months after the first
and 2 months after the second infusion, respectively. The
fourth patient (case 11 in part 3 [31]) developed severe bilat-
eral ON three months after the second infusion (i.e. four
months after the first infusion) of rituximab. A fifth patient de-
veloped two attacks of myelitis and of ON 2 months after the
first and three months after the second infusion. Finally, one
patient who was treated with rituximab for a first attack of
myelitis, developedON just fivemonths after the first infusion
of 1000 mg rituximab. By contrast, no early relapses were
noted in ten cases.
Of note, two end-of-dose relapses in rituximab-treated
patients were documented. One patient (see case 7 in part
3 [31]) relapsed immediately after reappearance of B cells
9 months after the first infusion. Similarly, a relapse
occurred in case 6 12 months after the first rituximab infu-
sion. By contrast, CD19 cells were still undetectable and no
new relapse has occurred 14 months after onset in case 12.
In one patient (case 13 in part 3 [31]), therapy with rituxi-
mab had to be discontinued due to an allergic exanthema.
A single patient was treated with ofatumumab (18 months,
four cycles to date). While eight attacks of ON and three at-
tacks of myelitis (one with accompanying brainstem enceph-
alitis) had taken place over a period of 63 months under
various previous therapies (ARR 2.1), only a single attack of
ON occurred during 18 months (ARR 0.66) of ofatumumab
treatment in this patient.
Response to mitoxantrone and other rare therapies
In the only patient with available data (case 1 in part 3 of
this article series [31]), three infusions of mitoxantrone (1 ×
12 mg/m2 and 2 × 8 mg/m2) did not prevent three relapses
of myelitis and two of ON within around 5 months, with
some of the relapses occurring just a few weeks after infu-
sion. A further patient (case 13 in part 3 [31]) experienced
a relapse of sensory myelitis 1 month after initiation of fin-
golimod. Discontinuation of fingolimod after 3 months due
to lymphopenia was immediately followed by a relapse of
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myelitis with impaired ambulation, paresthesia and
dysesthesia below T5, and two flare-ups over the next
2 months, requiring a total of three cycles of (escalat-
ing) high dose IVMP therapy.
Ciclosporin was used in combination with MTX and oral
steroids in a single patient (see case 6 in the Appendix) for
a period of 6 months; no relapses occurred under this regi-
men. One patient (see case 13 in part 3 [31]) was treated
for 4 months with dimethylfumarate. While no relapses oc-
curred during that period, treatment had to be discontin-
ued due to reflux, pharyngitis and laryngitis.
Another patient (case 2 in part 3 [31]) was treatedwith IVIG
over 11months (and tapering of oral steroids during the initial
3 months). No new relapses occurred during that period and
IVIG treatment was temporally associated with clinical im-
provement and resolution of MRI lesions; the patient was still
relapse-free 12months after discontinuation of IVIG.
Long-term outcome
At last follow-up, VA was impaired in at least one eye in
21/38 (55.3%) patients with a history of clinical ON (me-
dian observation time 53.5 months, range 1-507) and
around one third (14/38; 36.8%) of all patients were either
functionally blind at last follow-up in one eye or both or
had a severe visual impairment (VA >0.1 and ≤0.5). Func-
tional blindness (VA ≤0.1) in at least one eye was noted in
10/38 (26.3%) patients, severe visual impairment but no
functional blindness (VA >0.1 and ≤0.5) in 4/38 (10.5%),
moderate impairment (VA >0.5 and ≤0.75) in 2/38 (5.3%),
and mild impairment (VA >0.75 and <1.0) in 5/38 (13.2%).
Both optic nerves had been affected at least once at last
follow-up (median observation time 54 months, range 1-
394), either clinically or subclinically (i.e., based on MRI,
VEP, fundoscopy, and/or OCT findings only) and either
simultaneously or successively, in 35/42 (83.3%) patients,
while only one optic nerve had been affected in the remain-
der (median observation time 29.5 months, range 5-507).
Severe paresis was present at last follow-up in 1/28
(3.6%) patients with a history of clinical myelitis (me-
dian observation time 41.5 months, range 6-102),
moderate paresis in 4/28 (14.3%), and mild paresis in 6/28
(21.4%). Ambulation was impaired at last follow-up due to
paresis and/or gait ataxia in 25%.
If the total cohort is considered, VA was reduced at last
follow-up in 23/47 (48.9%) patients with available data
(median observation time 49 months, range 1-507) and
paresis was present in 14/48 (29.2%) (median observation
time 50.5 months, range 1-507).
EDSS at last follow-up
The expanded disability status scale (EDSS) was developed for
use in classical MS and strongly focuses on ambulation defi-
cits [47]. When interpreting EDSS results, it should be taken
into consideration that complete bilateral visual loss corre-
sponds to an EDSS score of just 4 and that patients with iso-
lated ON can reach no higher scores. In accordance
with that well-recognized underrepresentation of visual
deficits – the main long-term sequelae in our patients
(with functional blindness or severe visual loss present
in 36%) – EDSS scores were nominally low at last
follow-up in most cases (median 2.5 [range 0-10] in the
total cohort, N= 47, and 3 [range 0-10] among patients with
relapsing disease, N= 40). A median EDSS ≥3.5 was reached
after more than 60 months (Fig. 12). The median EDSS was 3
(range 1-10) among patients with an observation period of
≥100 months (n = 12) and 3.25 [range 1.5-10] among patients
with an observation period of ≥120 months (n= 8). A higher
median EDSS at last follow-up was noted in women (3, range
0 -10; n = 35) than in men (1, range 0-6; n= 12; p < 0.05) des-
pite a longer median observation period in themale subgroup
(72months [range 1-127] vs. 50.5months [range 1-507]).
Survival rate
After a median follow-up period of 52 months (range 1-
507), 49/50 (98%) patients were still alive. One patient
died from severe brainstem encephalitis leading to re-
spiratory insufficiency 123 months after disease onset
and after a total of 27 attacks, including attacks of ON,
myelitis, encephalitis and/or brainstem encephalitis (see
case 1 in part 3 of this article series [31]).
Fig. 12 Increase in median EDSS scores with observation time in 47 MOG-IgG-positive patients
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Discussion
MOG-IgG-positive ON and myelitis are increasingly recog-
nized as important differential diagnoses of AQP4-IgG-
positive NMOSD. Here, we comprehensively analyzed the
clinical, laboratory, radiological, and electrophysiological
features of one of the largest cohorts of MOG-IgG-positive
patients reported to date, as well as treatment responses
and long-term outcomes. In our cohort, which was charac-
terized by the longest observation time so far (mean 75 ±
46.5 months since onset, median 52 [1-507] months), the
disease took a relapsing course in most cases. Attacks were
often severe and characterized by substantial visual loss or
by paresis with longitudinally extensive spinal cord inflam-
mation. Many patients had radiological and/or clinical signs
of brain and brainstem involvement. While a relatively fa-
vorable long-term outcome was noted in the majority of
cases, the disease caused persistent severe visual impair-
ment including unilateral blindness in more than one third
of all patients with a history of ON, persistent mild to severe
paresis or gait ataxia in almost 50% of all myelitis patients,
and was fatal in one patient due to recurrent brainstem at-
tacks. Flare-ups after steroid treatment were noted in more
than 40% of cases, and even PEX was not always effective.
In around 70% of our patients, relapses occurred despite
immunosuppressive therapy at least once. Given that gen-
etic factors have been suggested to play a role in NMO, it is
a potential strength of the present study that the cohort in-
vestigated here was genetically relatively homogeneous, with
all patients except one being of Caucasian origin.
In this study, MOG-IgG were detected by means of new
generation cell-based assays (CBA) employing recombinant
full-length human MOG instead of enzyme-linked immu-
noassays, which are prone to both false-negative and false-
positive results and which are no longer recommended for
clinical routine diagnosis of MOG antibodies [10]; a CBA
was also used for detection of AQP4-IgG [7, 8].
Substantial phenotypic overlap with AQP4-IgG-positive
NMOSD and MS
MOG-IgG-positive myelitis and ON showed a significant
overlap with AQP4-IgG-positive NMOSD in clinical and
radiological presentation, with more than 60% patients with
a history of both ON and myelitis meeting Wingerchuk’s
2006 criteria for NMO [28] and around a third of all pa-
tients fulfilling the revised 2015 criteria [29]. Even manifes-
tations considered relatively typical for AQP4-IgG-positive
NMOSD, such as medulla oblongata lesions and intractable
nausea and vomiting or ON with involvement of the optic
chiasm, were noted in some cases. Moreover, MS was ini-
tially suspected in more than a third of all patients, and
every fourth patient with MOG-IgG-positive ON and/or
myelitis presenting with brain and/or brainstem lesions met
Barkhof ’s criteria for MS, demonstrating a substantial
phenotypic overlap between these two conditions.
With the discovery of AQP4-IgG [1, 6, 48], MOG-IgG
[10], N-methyl-D-aspartate receptor-IgG [49], and a
plethora of often non-paraneoplastic autoantibodies
identified in acute CNS inflammation over the past dec-
ade [50–54], including in patients with primary or sec-
ondary demyelination, it becomes increasingly clear that
not all patients presenting with relapsing CNS disease
of putative autoimmune etiology have classical MS –
even if they formally meet the ‘positive’ clinicoradiologi-
cal criteria for MS [46]. MOG-IgG-positive patients in
whom the disease starts with isolated brain or brainstem
involvement are particularly challenging. Thus more
and more importance attaches to carefully considering
the ‘negative’ criterion of ruling out other diagnoses
(“no better explanation”) included in the current diag-
nostic consensus criteria for MS [46].
Of note, 11 patients who met the clinicoradiological cri-
teria for MS and 11/14 patients in whom a diagnosis of MS
was initially suspected by their then treating physicians
were negative for CSF-restricted OCB. Similarly, many pa-
tients with AQP4-IgG-positive NMO who were falsely di-
agnosed with MS in the past were negative for OCBs in a
previous study [34]. This suggests that CSF analysis should
be re-included in the diagnostic criteria for MS as an im-
portant tool to exclude alternative diagnoses, as previously
recommended by us and others [55]. Moreover, 11/16 pa-
tients in whom MS had been initially suspected, later devel-
oped LETM lesions, which are not typically present in
classical MS. In total, 15 out of the 16 patients were either
negative for OCBs or had LETM lesions.
Most patients have relapsing disease
The relatively long observation time is a particular strength
of the present study, since it allows assessment of disease
course and outcome in the long run. While previous stud-
ies with shorter observation periods (12 months in [13],
18 months in [11], 2 years in [12]) and smaller sample sizes
(4 patients in [13], 9 in [11], 16 in [12]) suggested that
MOG-IgG-positive patients might often have monophasic
disease, our series demonstrates that most MOG-IgG-
positive patients with ON or myelitis have a relapsing dis-
ease course. Moreover, a very short median time to first re-
lapse of just 5 months was noted in this cohort, indicating
an overall high risk of early relapse in MOG-IgG patients.
Given that (i) the observation period among ‘monopha-
sic’ patients was significantly shorter than in the relapsing
subgroup and below the median time to relapse in around
one third of the ‘monophasic’ patients, (ii) the proportion
of relapsing patients increased with observation time
(Fig. 2), and (iii) the interval between the first and the sec-
ond attack was long in some of the relapsing cases
(>12 months in eight; up to 492 months), it is conceivable
that some of the few ‘monophasic’ patients will develop
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further attacks in the future. A monophasic course of dis-
ease might thus be even less common than suggested here.
On the other hand, time since onset was >5 years at last
follow-up in 3 patients in the monophasic group, all of
whom were not treated with immunosuppressants, so the
disease may in fact follow a monophasic course at least in
small proportion of cases.
Similarly, the significantly shorter observation time since
onset in patients with a history of ON but no myelitis or of
LETM but no ON than in patients with a history of both
ON and myelitis (i.e., NMO) suggests that the differences in
presentation between these groups are probably an effect of
observation time and that some of our patients with isolated
ON may develop myelitis in the future and some of those
with isolated LETM may develop attacks of ON. Indeed,
disease had started with either isolated ON or isolated mye-
litis (rather than simultaneous ON and myelitis) in around
three fourths of patients with a diagnosis of NMO at last
follow-up. Importantly, myelitis occurred only after several
ON attacks in some of these patients and ON only after
several myelitis attacks in others. Similarly, disease starts
with isolated ON or myelitis rather than simultaneous ON
and myelitis in the vast majority of AQP4-IgG-positive pa-
tients [34].
These findings are highly important when it comes to
deciding whether to treat MOG-IgG-positive patients or
not. The frequently relapsing course observed in the
present cohort indicates that prophylactic long-term im-
munotherapy should be considered in MOG-IgG-positive
patients. Given that a relapsing course was also noted in 5/
8 (63%) patients with onset under the age of 18, this might
possibly hold true also for children and adolescents. Studies
systematically investigating the efficiency of long-term
immunosuppression and/or immunomodulation in MOG-
IgG-positive ON and myelitis are therefore strongly war-
ranted. Moreover, given the lack of systematic long-term
treatment data in MOG-IgG-positive disease, currently
planned or ongoing treatment trials in NMO that include
AQP4-IgG-negative patients should consider testing for
MOG-IgG to allow subgroup analyses.
Severe attacks and unfavorable long-term outcome are
relatively frequent
Severe attack-related disability was noted in many cases, in-
cluding tetraparesis in around 30%, severe motor dysfunc-
tion with MRC grades ≤2 in around 25%, pain -and/or
dysesthesia in around 70%, bladder and bowel disturbances
in around 70%, functional blindness in almost 75%, bilat-
eral optic nerve damage in 51%, scotomas in 66%, and
brainstem encephalitis with, among other symptoms,
ataxia, intractable nausea and vomiting or, of particular
note, attack-related respiratory insufficiency in two patients,
which was fatal in one. Importantly, long-term outcome
was characterized by marked persisting visual impairment
or blindness and/or significantly impaired ambulation in
40%. Moreover, inflammatory damage was noted in the en-
tire CNS, with the spinal cord, optic nerves, brainstem, di-
encephalon, cerebellum, and telencephalon affected in
individual patients. These findings, together with the mostly
relapsing course observed in our patients, underline that
MOG-IgG-related CNS autoimmunity is a severe condition
that requires consistent treatment and care.
Although a favorable outcome was noted in several pa-
tients, our findings do not support the notion that MOG-
IgG seropositivity generally denotes a mild disease course
[11, 13]. Again, previous studies reporting such findings
may have been unintentionally biased by short observation
periods and small sample size.
It should be taken into account in both epidemiological
and therapeutic studies in the future that optic nerve dam-
age is the leading manifestation of MOG-IgG-positive auto-
immunity and that MOG-IgG-positive patients may present
for many years or decades with isolated ON. The EDSS,
which was developed for use in classical MS and which
largely focuses on ambulation, may not sufficiently reflect
the high degree of disability resulting from persisting visual
loss in a substantial number of MOG-IgG-positive patients.
Other scales of disability may need to be used in addition.
IVMP was not always effective and flare-ups were
frequent
In this context it is relevant that high-dose IVMP, though
effective in many cases, was followed by only partial recov-
ery or no recovery in 50% of all treated attacks. Moreover,
IVMP lead to only temporary improvement in 44% of all
patients at least once, resulting in flare-up of symptoms re-
quiring repeat or ultra-high-dose IVMP therapy. In at least
one case symptoms flared up not immediately after IVMP
treatment but in a delayed fashion after tapering of subse-
quent oral steroid treatment. In some cases, even ultra-
high-dose IVMP was ineffective or only transiently effective
with a second flare-up occurring shortly after. Interestingly,
in some patients IVMP was effective during initial attacks
but not later in the disease course.
The occurrence of cerebral venous sinus thrombosis in
one of our patients highlights the risks that repeat IVMP
therapy and escalation to ultra-high-dose IVMP carry.
It is unknown why IVMP was effective during some at-
tacks but not all. However, timing issues and differences in
antibody titers, other immunological parameters (e.g., T cell
activation), IVMP dosage, and previous or concomitant
treatments might play a role.
Given the high frequency of flare-ups observed in our co-
hort, close clinical monitoring after acute attack therapy for
MOG-IgG-positive ON and/or myelitis is recommended.
Moreover, oral tapering of corticosteroid therapy as well as
additional PEX treatment (see below) should be considered.
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MOG autoimmunity may underlie CRION in a subset of
patients
Given the high proportion of patients with flare-up of
ON after steroid withdrawal, i.e., of steroid-dependent
ON, we propose that a subset of patients previously
diagnosed as having CRION [56] may in fact have
MOG-IgG-positive ON. Indeed, at least 3 of our patients
had received a diagnosis of CRION before MOG-IgG
was detected. Testing of larger cohorts of patients with
CRION for MOG-IgG is highly warranted.
PEX treatment was often followed by full or partial recovery
PEX was used in most cases as rescue therapy if steroids did
not result in complete recovery; only in four patients was PEX
used as first-line treatment for acute attacks. Of note, PEX
treatment (as stand-alone therapy or following IVMP) was
followed by complete or almost complete recovery in a sub-
stantial number of attacks (around 40%). For example, in case
2 ON symptoms flared up twice after high-dose and subse-
quent ultra-high-dose IVMP therapy; only PEX ended the at-
tack and was followed by complete recovery. The efficacy of
PEX in this and other cases of MOG-IgG-positive ON and/or
myelitis has potentially important pathophysiological implica-
tions, since it suggests a direct pathogenic role of the antibody.
Interestingly, PEX treatment stopped the progression of
dysesthesia in case 9, one of only 3 cases inwhich a slowly pro-
gressive (yet also relapsing) course of disease was noted.
However, as a limitation, it should not be overlooked that
in almost 60% of attacks treated with PEX, and thus in the
majority of cases, only partial recovery was achieved, and in
2 cases there was no response to PEX. The variability in re-
sponse to PEX may be linked to differences in PEX timing;
MOG-IgG titers; intensity, extension, and site (e.g., ON vs.
myelitis as seen in AQP4-IgG-positive NMOSD [35]) of in-
flammation; and, importantly, the number of PEX courses
applied, which varied between 3 and 11 in the present
cohort. Preliminary findings from our laboratory (S.J., un-
published data) show that AQP4-IgG and MOG-IgG may
remain detectable even after five to seven plasma ex-
changes, raising the question of whether PEX treatment is
discontinued too early in some cases. This is also supported
by the early reoccurrence of attacks in cases 1 and 9 in part
3 of this series [31], just 1, 2 and 3 months after PEX. Alter-
natively, T cell-mediated mechanisms might play a more
important role than antibody-mediated mechanisms in
patients who do not sufficiently respond to PEX.
On the understanding that the use of PEX after IVMP
implies previous IVMP failure, only incomplete recovery or
no recovery at all was achieved in around 60% of all attacks
treated with IVMP (N = 147). Twenty-five of those attacks
were subsequently treated with PEX, and full recovery was
achieved in 40% of them. This would suggest a beneficial
role of PEX in MOG-IgG-positive patients with IVMP
failure, similar to what has been observed in AQP4-IgG-
positive NMOSD [35]).
The overall good response to escalatory PEX therapy,
together with the risks associated with extensive corti-
sone pulse therapy as highlighted by the occurrence of
sinus thrombosis with brain edema and seizures in case
2 might suggest that PEX treatment should be consid-
ered more often in patients with MOG-IgG-positive ON
and/or myelitis. PEX may be considered as a substitute
for escalatory ultra-high-dose IVMP therapy for severe
attacks, particularly in patients who have responded well
to PEX in the past. However, the observation of urosep-
sis in case 1 of part 3 [31] after several cycles of PEX il-
lustrates that attention must be paid also to risks
associated with PEX and IA, especially if those treat-
ments are applied repeatedly and in combination with
IVMP or IS treatment.
Breakthrough attacks despite long-term immunotherapy
Similarly, long-term IS and IM treatments were not always
effective in preventing further relapses. Almost 70% of all
patients treated with IS or IM drugs developed at least one
attack during therapy. This included patients receiving
AZA, MTX, NAT, IFN-beta, GLAT, rituximab, ofatumu-
mab, and mitoxantrone. In case 6 at least 12 attacks of ON
and myelitis occurred under various immunotherapies,
and as many as 15 attacks occurred in case 1 in part 3 of
this article series [31].
Complications of IS/IM therapy were rare in this cohort
and included condylomata acuminata requiring surgical
treatment, elevated liver enzymes under AZA treatment,
and an allergic reaction to rituximab.
AZA failure was associated with latency period and lack
of cotreatment
AZA, which has been previously reported to be
partially effective in NMO [57–59], including in
AQP4-IgG-positive NMOSD [60], was the most com-
monly applied IS therapy in our cohort. However,
more than 80% of all AZA-treated patients experi-
enced at least one attack while under therapy. As
AZA has a latency period of 3-6 months during
which cotreatment with oral steroids has been recom-
mended [33], we analyzed the temporal pattern of
AZA failure. Of 34 attacks during AZA treatment, 14
(41.2%) took place during the first 6 months (11 dur-
ing months 1-3 and 3 during months 4-6). Further-
more, 12 of those 14 attacks (85.7%) occurred in patients
(n = 6) not cotreated with oral steroids, PEX, or other im-
munosuppressants during that period. This suggests that
AZA failure in MOG-IgG-positive patients may be caused
in a substantial proportion of cases by the drug’s well-
known latency in efficacy. Moreover, it may indicate that
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cotreatment with oral steroids during the initial
6 months of AZA treatment should not be abandoned
in MOG-IgG-positive patients, provided contraindications
have been excluded. However, it must be mentioned as a
potential limitation that AZA was discontinued early in
some patients after breakthrough attacks occurred, which
may have introduced a considerable bias towards a higher
proportion of attacks in the first 6 months. Larger studies
are therefore needed before any treatment recommenda-
tions can be made.
Future studies on the efficacy of AZA and oral steroids
as well as on that of oral steroids as stand-alone therapy
in MOG autoimmunity should take into account that a
recent retrospective analysis suggested a better response
rate to high-dose azathioprine (2.5-3 mg/kg) than to
standard treatment (1-1.5 mg/kg) in AQP4-IgG-positive
NMOSD [58]. Whether such a high-dose regimen is also
required in MOG-IgG-positive patients is currently
unknown.
Low relapse rate under MTX in most but not all cases
A recent study suggested that MTX might be effect-
ive in patients with AQP4-IgG-positive NMOSD [33,
61]. In our cohort, eight MOG-IgG-positive patients
with ON and/or myelitis were treated with MTX, and
exact data on attack dates were available from six. A
lower relapse rate than in the total cohort and long
attack-free intervals were observed in most MTX-
treated patients. Based on these preliminary yet
promising results, further retrospective studies seem
warranted to assess the efficacy of MTX in MOG-
IgG-positive ON and/or myelitis.
Attacks related to initial rituximab infusion and reappearance
of B cells
Rituximab treatment was followed by a clear reduction in
relapse rate in three out of nine patients. In the six
remaining patients, relapses occurred 2, 3, 4, 4, 7, 8, 8, 12
and 20 weeks after the first or second infusion (in one
case despite PEX treatment 1 month earlier). This is
reminiscent of the transient deterioration reported in
some patients with AQP4-IgG-positive NMO after
commencement of rituximab, which is associated with an
temporary increase in BAFF and autoantibody levels [62,
63]. Another MOG-IgG-positive patient who experienced
postinduction relapses (three within 3 months) has re-
cently been described [63]. Whether cotreatment with ste-
roids can prevent such events still needs to be explored.
Of note, one patient relapsed immediately after re-
appearance of B cells. This is similar to what has been
observed in AQP4-IgG-positive NMO patients [64, 65]
and suggests that (i) B cells should be closely monitored
in MOG-IgG-positive patients treated with rituximab
and (ii) treatment intervals should be short and doses
high enough to prevent B cell reappearance. Rituximab
has also been found to be effective in AQP4-IgG-
positive NMOSD in some studies [65, 66], though not in
all [67].
Ofatumumab is a fully human anti-CD20 monoclo-
nal antibody which targets an epitope distinct from
that of rituximab [68]. The marked reduction in re-
lapse rate in the single patient treated with ofatumu-
mab in this study is promising. However, more data
are needed before any recommendations can be made.
To the best of our knowledge this is the first report
on ofatumumab both in MOG-IgG- and in AQP4-
IgG-associated EM.
Ongoing or increasing disease activity under IFN-beta
In the present cohort, 4 patients were treated with
IFN-beta. All 4 showed ongoing or increasing disease
activity. Although preliminary, these data suggest that
IFN-beta, which has already been shown to be inef-
fective and to cause disease exacerbation in AQP4-
IgG-positive NMOSD [69–72], may also be ineffective
or even detrimental in MOG-IgG-positive patients.
Given the substantial clinical overlap between MOG-
EM and conventional MS, a condition often treated
with IFN-beta, this would be of high clinical rele-
vance. Larger retrospective studies evaluating the effi-
cacy of IFN-beta in MOG-IgG-positive EM are
therefore highly warranted.
Preliminary data do not support use of GLAT or NAT
Like IFN-beta, GLAT is frequently used to treat
patients with conventional MS. With the efficacy of
GLAT being equivocal in two patients and eight
breakthrough attacks having occurred in another
three, the use of GLAT cannot currently be recom-
mended in MOG-IgG-positive EM. Of note, GLAT
has also been suggested to be of no clear benefit in
patients with AQP4-IgG-associated NMOSD [36].
NAT, another drug shown to be beneficial in MS,
could not prevent relapses in three MOG-IgG-
positive patients in our cohort. While these prelim-
inary data are not supportive of the use of NAT in
MOG-IgG-positive ON or myelitis, systematic stud-
ies are certainly needed before definite conclusions
can be drawn. NAT has also been found to be inef-
fective or even detrimental in patients with AQP4-
IgG-positive NMOSD in recent studies [73–75]. Nu-
merous relapses also occurred in a patient treated
with mitoxantrone, another agent considered effect-
ive in conventional MS.
The failure of the MS therapeutics IFN-beta, GLAT
and NAT in many of our patients supports the view that
classical MS and AQP4- or MOG-IgG-associated disor-
ders differ in terms of immunopathogenesis. This stance
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is further supported by the lack of OCB, a hallmark of
conventional MS, in most of our MOG-IgG-positive pa-
tients as well as in most patients with AQP4-IgG-
positive NMOSD [34, 76].
MOG-IgG needs to be considered in children as well as in
elderly patients
The median age at onset was around 30 years, which is
similar to MS but differs from that in AQP4-IgG-
positive NMOSD (~39) [34] by almost 10 years. How-
ever, the youngest patient in this cohort was just 6 years
of age at onset and the oldest experienced his first attack
at age 70, suggesting that MOG-IgG-positive ON and/or
myelitis – just like AQP4-IgG-positive NMOSD [34] –
can occur irrespective of age and need to be considered
also in children and in the elderly.
All four patients with onset during childhood (at the
ages of 6, 10, 12, and 12 years) initially presented with
ON (bilateral in three), accompanied by myelitis in only
one of them. Similarly, disease started with ON in the
four oldest patients (onset at 58, 64, 66 and 77 years). Of
note, 8/11 (73%) patients with onset at age <20 had a
recurrent disease course at last follow-up, which led to
relevant disability in 5 of them (EDSS 3.5, 3.5, 6.0, per-
manent unilateral blindness, and VA of 0.2, respectively,
at last follow-up), and in one of the two remaining pa-
tients observation time was too short to rule out relaps-
ing disease. This would argue against the notion that
MOG-IgG-positive ON in young patients is generally a
monophasic disease and suggests that long-term im-
munotherapy (e.g., with IVIG if immunosuppressants
are to be avoided) should be considered also in children
and adolescents; however, larger studies are certainly
needed. A recurrent course was also present in three of
the four oldest patients in this cohort.
Interestingly, the time between onset and first relapse
was extraordinarily long in one of our patients (see case
6 in part 3 of this series [31]), who had suffered from a
first attack of ON at age 12, followed by an LETM attack
41 years later. Of note, two further patients reported
events during childhood that are compatible with a first
attack of MOG-IgG-positive EM (two episodes of bulbar
movement pain, diplopia, and headache at ages 10 and
11 in case 23, and “neurogenic diabetes insipidus” at age
7 in case 22). As it remains unclear whether those early
events were caused by the same disorder as the patients’
more recent complaints, which started 18.5 and 22 years
later, they were not considered for statistical analysis.
With an age at onset of 70 years, patient 20 is, to the
best of our knowledge, the oldest Caucasian MOG-IgG
patient reported to date. The youngest patient described
in the previous literature was just 1 year of age [77] and
the oldest, a Japanese patient, 70 years [12] at onset.
Similarly, AQP4-IgG-positive NMOSD has been de-
scribed both in children and in elderly patients [78–81].
Accordingly, MOG-IgG-positive EM is an important
differential diagnosis of AQP4-IgG-positive NMOSD ir-
respective of age.
Women are more often affected than men
Women outnumbered men by a factor of around 2.8 in
this study. Female gender has also been identified as a risk
factor for AQP4-IgG-positive NMOSD [82, 83]. However,
a significantly higher preponderance of women (a male to
female ratio of around 1:9) has been found in the latter
condition in Caucasian patients [34]. The ratio found
among MOG-IgG-positive patients in the present and
previous cohort is more similar to that found in AQP4-
IgG-negative NMOSD [34] and in classical MS [84].
Women might possibly be affected more severely than
men as indicated by a higher median EDSS at last follow-
up despite shorter median disease duration; however, con-
firmatory studies are needed to verify this finding.
Attacks may occur during pregnancy and post partum
The effect of pregnancy on MOG-IgG-positive EM has
not yet been systematically investigated. A recent study
(n = 16) indicated that pregnancy may negatively influ-
ence the disease course of NMO; however, no data on
the patients’ AQP4-IgG or MOG-IgG status were given
[85]. The authors found a significantly higher attack rate
in the first trimester after pregnancy and greater disabil-
ity progression 1 year after delivery [85]. In another co-
hort [86], 14/40 AQP4-IgG-positive patients developed
the first symptoms of NMOSD either during pregnancy
(n = 3) or within a year after delivery or abortion (n =
11). While the ARR during pregnancy did not differ
from that before pregnancy, it increased significantly
during the first and second trimesters after delivery;
moreover, 77% of all deliveries were associated with
post-partum relapses. In MS, pregnancy is thought to re-
duce the number of MS relapses, especially in the sec-
ond and third trimesters; although attack rates tend to
rise in the first 3-6 months post partum, no increased
long-term disability has been found. In the present co-
hort, around a quarter of MOG-IgG-positive women ex-
perienced one or more attacks during pregnancy or post
partum. Of special note, the disease started post partum
in three of these patients. This could indicate that preg-
nancy- and/or delivery-related immunological changes
may play a role both in triggering attacks and, possibly,
in disease induction. However, given that most attacks in
these patients as well as in the total female subgroup oc-
curred irrespective of pregnancy and delivery, other risk
factors may be more important. Based on these data,
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systematic prospective studies on the role of pregnancy
and delivery in MOG-IgG-positive EM are warranted.
Attacks may follow infection or vaccination
Attacks were preceded by infection in around 40% of
patients at least once, and disease started shortly after
an infection in at least 11 cases and after vaccination in
two cases. This is similar to AQP4-IgG-positive
NMOSD, which has been reported to be preceded by in-
fection in 20-30% of cases [34, 87]. Acute infections are
also thought to trigger clinical attacks in classic MS.
However, the exact relationship between infection or
vaccination and MOG-IgG-positive EM is unknown.
While there is no evidence yet for molecular mimicry, it
is conceivable that infection-associated immunological
changes and/or blood-brain barrier disruption could
promote CNS lesion formation. In AQP4-IgG-positive
NMOSD, acute relapses are indeed associated with an
elevated QAlb, which can be caused by structural barrier
damage [76, 88]. QAlb was also elevated in around one
third of MOG-IgG-positive patients in the present study.
As a limitation, QAlb likely also reflect changes in the
CSF flow rate [45]. It is of potential interest and deserves
further investigation that the two post-vaccinal cases
both occurred after vaccination against tetanus, diph-
theria and pertussis. Of note, both patients developed re-
lapsing disease. This is different from conventional
postvaccinal ADEM, which is usually monophasic.
CSF findings differ from MS but mimic AQP4-IgG-positive
NMO
Examination of CSF harbors important potential for differ-
entiating classical MS and MOG-IgG-positive EM but not
MOG-IgG-positive EM and AQP4-IgG-positive EM: As in
AQP4-IgG-positive patients [76], OCB and a positive IgG
CSF/serum ratio, which are present in most patients with
MS and which are thus considered a diagnostic hallmark of
that disease, were missing in around 90% of our MOG-
IgG-positive patients. Moreover, OCB disappeared later in
2 out of the 6 only OCB-positive patients; by contrast, OCB
are considered to remain stable for decades in MS [89].
Finally, neutrophil granulocytes, which are also present in
AQP4-IgG-positive NMO [34, 76, 90] (as well as in bacter-
ial meningoencephalitis [91]), were found in the CSF at
least once in 64% of cases, but are absent in classical MS.
Missing OCB or granulocytic pleocytosis should thus
prompt physicians to challenge the diagnosis in patients
with suspected MS and to consider MOG-IgG- or
AQP4-IgG-positive encephalomyelitis.
Subclinical evidence for dissemination in space
Electrophysiological evidence for optic nerve damage
was present in at least 3 patients with no history of clin-
ically apparent ON, and for spinal cord damage in at
least 3 patients with no history of clinically apparent
myelitis in our cohort. Similarly, supratentorial, brainstem,
or cerebellar MRI lesions were present in 21 patients who
had never shown clinical signs of encephalitis or cerebelli-
tis but only of ON and/or myelitis. Finally, spinal cord
MRI lesions were detected in 2 patients with ON but no
history of clinical myelitis. This indicates that subclinical
inflammation occurs in some cases and that clinical exam-
ination needs to be complemented by electrophysiology
and MRI to assess the real extent of CNS inflammation in
MOG-IgG-positive patients.
If not only clinical attacks are taken into account but
also clinically silent lesions as detected electrophysiologi-
cally or by MRI, evidence for dissemination in space
(defined as involvement of more than one of the follow-
ing structures: optic nerves, spinal cord, supratentorial
brain, brainstem, cerebellum) was present at last follow-
up in 37/50 or 74% of patients, compared with 26/50 or
52% based solely on clinical grounds.
VEP and SSEP were not considered in the 1999 and 2006
diagnostic criteria for NMO, which required clinically
apparent attacks of myelitis and ON, and are still not
considered in the 2015 criteria for NMOSD [29]. System-
atic studies on the potential prognostic, diagnostic, and
therapeutic implications of pathological EP and MRI find-
ings suggesting dissemination in space in patients with
MOG-IgG-positive isolated ON or isolated myelitis are
warranted. Evidence for subclinical optic nerve damage has
also been reported in AQP4-IgG-positive NMOSD [92].
Bilateral ON and simultaneous ON and myelitis are
common at onset
More than 40% of all patients with a history of both
ON and myelitis at last follow-up presented with simultan-
eous myelitis and ON at least once, which is not different
from what has been described in AQP4-IgG-positive NMO
(42% according to [34]). However, the frequency of simul-
taneous myelitis and ON at disease onset, i.e., as the initial
presentation, was much higher in MOG-IgG-positive pa-
tients (23% of all patients with a history of ON and myeli-
tis) than in AQP4-IgG-positive NMOSD patients (6.7%
according to [34]; p < 0.03). Similarly, bilateral ON at onset
was more frequent in MOG-IgG-positive patients with a
history of ON (35%) than in AQP4-IgG-positive NMOSD
patients with a history of ON (14.3% [34]; p < 0.04 ). Simul-
taneous ON and myelitis as well as bilateral ON at onset
may thus be of diagnostic value and should prompt physi-
cians to consider MOG-IgG testing.
Short spinal cord lesions do not preclude MOG-IgG
positivity
Spinal cord MRI lesions extending over three or more
vertebral segments (so-called LETM) are considered a
hallmark of AQP4-IgG-positive NMOSD, but are usually
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not found in classical MS. The presence of an LETM le-
sion in addition to clinical myelitis was also listed as a
supportive criterion in the 1999 diagnostic criteria for
NMO and one of three minor characteristics, two of
which had to be present in addition to a history of ON
and myelitis before a diagnosis of NMO could be made,
in the 2006 criteria [28]. The association of MOG-IgG
with LETM found in this and in previous studies is
therefore of differential diagnostic importance.
However, two recent studies could demonstrate that
up to 15% of all MRIs of AQP4-IgG-positive patients
show non-longitudinally extensive lesions [34, 93]. Simi-
larly, lesions never exceeded two vertebral segments in 8
of our MOG-IgG-positive patients; in another 10 pa-
tients, at least one MRI showed only a non-LETM lesion
but longitudinally extensive lesions were present in pre-
vious or later MRI examinations. The presence or ab-
sence of ‘short’ lesions in patients with AQP4-IgG- or
MOG-IgG-positive myelitis is thought to depend,
among other factors, on timing issues [94]. If MRI is
carried out very early in the attack course or long
time after an acute attack, lesions may be still evolv-
ing or be already in the process of resolution,
respectively.
Similar to AQP4-IgG-positive myelitis, more than
one lesion in the same MRI and swelling of the spinal
cord were detected in many patients at least once. By
contrast, necrotic lesions leading to spinal cord cavi-
tation, as sometimes noted in AQP4-IgG-positive
myelitis, were not reported in any of our MOG-IgG-
positive patients.
Lesions may affect the entire visual pathway
While retrobulbar optic neuritis was highly common
among our MOG-IgG-positive patients, lesions affecting
other parts of the optic pathway should be taken into
consideration as well in MOG-IgG-positive patients pre-
senting with visual symptoms. Many patients had signs
of papillitis as detected fundoscopically; evidence for in-
flammation of the anterior part of the optic nerve was
also found by MRI (Fig. 9). However, some patients pre-
sented with lesions in the chiasm (Fig. 9) and/or with
longitudinally extensive ON (LEON) affecting both the
anterior and the posterior portion of the optic nerve.
Both LEON lesions and chiasmatic lesions were previ-
ously thought to be indicative of (AQP4-IgG-positive)
NMOSD [29]. Our findings are in line with a recent
Australian study that reported greater optic nerve lesion
lengths in MOG-IgG-associated ON and AQP4-IgG-
associated ON than in MS-related ON [95]. In a single
patient, visual disturbances were associated with lesions
within the optic tract (Fig. 9). Finally, some patients had
occipital white matter lesions.
Perioptic contrast enhancement warrants further
investigation
As shown in Fig. 9, contrast enhancement was not only
seen within the optic nerve but also in the perioptic
nerve sheath and the immediately surrounding orbital
tissue. This imaging pattern is of potential differential
diagnostic relevance and, thus, deserves to be further in-
vestigated. In accordance with this finding, Kim et al. in
a very recent study found perineural enhancement in 6
of 18 MOG-IgG-positive patients [96]. As is the case
with other MRI features, it is likely that the presence or
absence of that phenomenon depends on disease and
treatment status: more than one third of all MRIs with-
out perioptic enhancement in our cohort were per-
formed during remission, and some of the remaining
patients had been treated with high-dose IVMP before
the MRI was performed.
Coexisting autoimmunity is rare in MOG-IgG-positive
patients
Coexisting autoimmune disorders are present in more than
one third of AQP4-IgG-positive NMOSD patients [34]. By
contrast, only around 9% of our MOG-IgG-positive pa-
tients had a coexisting autoimmune disorder (2 × RA, 1 ×
Hashimoto thyroiditis, 1 × Grave’s disease). Systemic lupus
erythematosus, Sjögren syndrome, and myasthenia gravis,
which are common in AQP4-IgG-positive NMOSD
[97–102], were absent in all of our MOG-IgG-positive
patients. This is in line with a previous study that reported
a lower frequency of concomitant autoimmune disorders in
‘AQP4-IgG-seronegative’ NMOSD patients [34]. Interest-
ingly, first symptoms of anti-TPO-, anti-thyreoglobulin-,
anti-TSH receptor-associated hyperthyreosis appeared just
seven weeks after the first attack of MOG-IgG-positive
myelitis in one of our patients, suggesting that MOG auto-
immunity might have been part of a broader immune dys-
regulation in this case.
Nosological issues
The 2015 diagnostic consensus criteria for NMOSD de-
mand that “alternative diagnoses” should be excluded [29].
However, it remains unclear whether MOG-IgG-positive
ON or myelitis should be considered an “alternative
diagnosis” or not [103–105]. AQP4-IgG-positive and
MOG-IgG-positive EM differ in terms of target structures
(astrocytes vs. oligodendrocytes) and, accordingly, immu-
nohistopathology [18–20], but MOG-IgG is not explicitly
mentioned as an exclusion criterion. This mainly reflects
the fact that at the time the criteria were developed, data
on MOG-IgG-positive patients were still scarce.
In the present study, only around one third of all
MOG-IgG-positive patients met the clinical and radio-
logical criteria for “NMOSD without AQP4-IgG” [29]. If
MOG-IgG is not considered an exclusion criterion for
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NMOSD, this would result in a subset of MOG-IgG-
positive patients being considered eligible for clinical
studies and treatment trials, while others would be ex-
cluded based solely on phenotypic presentation and despite
all of these patients belonging to the same immunopatho-
genetically defined disease spectrum. This could introduce
a relevant inclusion bias given that almost all of the patients
who met the criteria had a history of ON and LETM (15/
16 or 94%), while most of those who did not meet the cri-
teria had isolated ON or isolated LETM at last follow-up
(27/34 or 79%). Conversly, inclusion of MOG-IgG-positive
patients in NMOSD cohorts (which are predominantly
AQP4-IgG-positive) would introduce bias as well.
We therefore believe that confirmed MOG-IgG sero-
positivity should be considered an exclusion criterion for
NMOSD and that the term ‘NMOSD’ should be restricted
to AQP4-IgG-positive patients and, possibly, double-
seronegative patients meeting the criteria for ‘AQP4-
IgG-negative NMOSD’ [29].
There are two potential limitations to such an approach.
First, using MOG-IgG seropositivity as an exclusion cri-
terion for NMOSD would require providing a reference
assay for MOG-IgG testing with excellent specificity as
established in an appropriately controlled multicenter set-
ting. Alternatively, however, diagnostic criteria for MOG-
IgG-positive NMOSD based both on serological and on
supporting clinicoradiological criteria could be established
in analogy to the current consensus criteria for NMOSD.
Second, so-called ‘double-positive’ patients, i.e., patients
positive for both AQP4-IgG and MOG-IgG, would pose a
diagnostic dilemma. However, such patients should in any
case be excluded from clinical trials as they may have two
immunopathophysiologically distinct diseases. Moreover,
‘double-positive’ patients seem to be extremely rare (see
part 1 of this article series [30] and Table 4 in [17]) and
the few cases reported so far worldwide have not been in-
dependently confirmed.
Limitations
We acknowledge some obvious limitations of our study.
First, the study design was retrospective, as in all previ-
ous studies in the field, and a high number of neuro-
logical centers were involved. However, due to the low
prevalence of the condition, prospective single-center
studies including sufficiently large numbers of patients
are impracticable. Moreover, the multicenter design of
this study, which included 11 academic centers, reduces
the risk of referral bias, which was acknowledged as a
possible limitation by the authors of previous large
single-center studies in the field of NMO [28, 106].
Moreover, reliable assays for detecting MOG-IgG have
only recently been developed; accordingly, only retro-
spective long-term data are currently available. Second,
patients with a benign or monophasic long-term course
are less likely to be admitted to hospital and might thus
be under-represented in the present cohort. However,
this type of potential bias is inherent in hospital-based
studies and cannot be completely avoided. It is import-
ant in this context that all centers involved in the
present study also have specialized outpatient clinics for
patients with neuroinflammatory conditions and that
participants were recruited among both inpatients and
outpatients. Moreover, the threshold for admission is low
in Germany and Italy, where public healthcare is free.
Third, MOG-IgG has also been reported in patients with
conditions classified as ‘ADEM’ based on clinical and
radiological features, especially in children [107]. Such
cases were not systematically included in the present co-
hort, which focused on patients with ON and/or myelitis.
Given that our study found a relapsing disease course in
most patients with MOG-IgG-positive CNS inflammation
and that attacks did not develop until years after initial
presentation in some cases, systematic follow-up studies
on patients previously diagnosed with MOG-IgG-positive
‘ADEM’ seem warranted to confirm that rare association.
Conclusions and outlook
In summary, our study demonstrates that MOG-IgG-
associated ON and myelitis frequently follow a relapsing
course and result in severe and/or persisting disability in
a substantial number of cases. Functional blindness due
to optic nerve damage is the most common disabling se-
quela. In addition to tetra- or paraparesis, dysesthesia
and pain are common symptoms in patients with myeli-
tis. Some patients experience mild attacks with purely
sensory symptoms that may not be accompanied by
marked MRI or electrophysiological changes. Although
in our cohort most patients with MOG-IgG-positive
myelitis had LETM, non-longitudinally extensive lesions
were found on a number of MRI examinations and thus
do not preclude the diagnosis. Coexisting clinical or
radiological evidence for brain, brainstem, or cerebellar
involvement is frequent and may be extensive in some
cases. Brainstem symptoms may include intractable
nausea and vomiting as well as life-threatening or fatal
respiratory complications. As in AQP4-IgG-positive
NMOSD, CSF examination reveals mostly mild pleocy-
tosis (partly with neutrophils) and, in contrast with MS,
no evidence of intrathecal IgG synthesis in the vast ma-
jority of cases. Treatment of acute attacks with IVMP
and PEX was effective in many patients, and immuno-
suppressive therapy was often followed by relapse-free
intervals; however, failure of acute and long-term treat-
ment and, subsequently, rapid accumulation of disability
was noted in several cases. Of particular note, flare-up of
symptoms after discontinuation of IVMP for treatment of
an acute attack is frequent in MOG-IgG-positive patients.
Full recovery was achieved by PEX in some cases,
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including patients showing IVMP failure. Breakthrough
attacks in AZA-treated patients occurred particularly dur-
ing the latency period of AZA and in patients not
cotreated with oral steroids. MTX was identified as a po-
tentially effective treatment in MOG-IgG-positive ON
and/or myelitis. IFN-beta was used in rare patients mis-
diagnosed with classical MS and was associated with an
increase in disease activity. Rituximab was effective in
some patients, but new attacks occurred within a few
weeks after the first infusion in a subset of cases, similar
to what has been reported in AQP4-IgG-positive
NMOSD. Our series, which includes some of the youngest
as well as the oldest Caucasian MOG-IgG-positive cases,
demonstrates that MOG-IgG positivity should be consid-
ered in patients presenting with ON or myelitis of un-
known origin irrespective of age. Women are affected
more often – and possibly more seriously – than men.
Coexisting autoimmunity in MOG-IgG-positive NMOSD
seems to be rare compared with AQP4-IgG-positive
NMOSD. A substantial overlap in clinicoradiological pres-
entation both with AQP4-IgG-positive NMOSD and with
classical MS was found, and many patients were initially
diagnosed with MS. While some patients with MOG-
IgG-positive ON and/or myelitis meet the 2015 inter-
national diagnostic criteria for NMOSD, others do not;
this is problematic from a nosological point of view, as-
suming that the same immunopathogenesis underlies
all MOG-IgG positive cases. Several clinical and radio-
logical features hitherto thought to be typical for
AQP4-IgG-positive NMO, such as longitudinally exten-
sive spinal cord lesions, lesion location in the central
portion of the spinal cord, longitudinally extensive
optic nerve lesions, lesions involving the optic chiasm,
area postrema lesions, intractable nausea and vomiting,
and thalamic lesions, or for MS, such as INO or peri-
ventricular, subcortical, juxtacortical, and callosal white
matter lesions, were present in some of our MOG-IgG-
positive patients. Similar to AQP4-IgG-positive
NMOSD and to MS, disease onset or relapse was pre-
ceded by infection or vaccination in several cases.
Around 30% of all the women in our cohort who gave
birth at least once developed attacks during pregnancy
or post partum.
Our findings from a predominantly Caucasian cohort
strongly argue against the notion that MOG-IgG denotes
a milder and usually monophasic variant of NMOSD, as
suggested by previous, smaller cross-sectional studies
with shorter observation periods. Given the relapsing
and often severe disease course of MOG-IgG-positive
ON and myelitis, the use of long-term immunosuppres-
sive treatments in this condition should be considered.
Prospective multicenter studies and treatment trials in
MOG-IgG-positive EM will be difficult to perform due
to the rarity of the condition but are highly warranted.
Appendix
Due to the novelty and rarity of the disorder, large and
comprehensive case series illustrating the broad and
heterogeneous spectrum of clinical manifestations, disease
courses, and radiological presentations in MOG-IgG-
positive encephalomyelitis are lacking. In this appendix,
we provide detailed reports on 28 cases of MOG-IgG-
positive ON and/or myelitis. We believe that case reports
can draw a more vivid ‘real-life’ picture of this rare dis-
order than statistical analyses alone. For the reader’s con-
venience, the most important findings are briefly
summarized and discussed in a comment at the end of
each report. Additional reports are to be found in the
“Case reports” section in part 3 of this article series [31].
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I. MOG-IgG-positive NMO without brain involvement
(cases 1-5)
II. MOG-IgG-positive NMO with brain involvement
(cases 6-10)
III. MOG-IgG-positive recurrent ON (cases 11-18)
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V. MOG-IgG-positive recurrent LETM (case 25)
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I. MOG-IgG-positive NMO without brain involvement
Case 1 – Recurrent LETM and ON resulting in persisting
unilateral functional blindness and optic nerve atrophy.
This Caucasian woman first presented with ON of the
right eye in 08/2004 at age 40. Symptoms completely
remitted after IVMP treatment. Since then, at least seven
relapses of unilateral ON have occurred, which have
successively affected both eyes and only partially
responded to IVMP or IVMP and PEX. In addition, she
experienced two attacks of myelitis, one with paraparesis
and bladder and bowel dysfunction (04/2009) and the
other with gait ataxia and sensorimotor paraparesis (08/
2011); spinal MRI showed LETM lesions extending from
C5 to Th2 (04/2009) and at T5 and T11 (08/2011), re-
spectively, with Gd enhancement. Multiple brain MRI
examinations were normal or showed only a few non-
specific lesions not meeting the Paty or Barkhof criteria
for MS; in addition, atrophy of both optic nerves was
noted. Electrophysiology revealed prolonged P100 laten-
cies in both eyes; later potentials were lost. While CSF was
negative for OCB, very mild pleocytosis (6 cells/μl) was
noted. The patient was given AZA (150 mg/d) between
01/2010 and 08/2010, and MTX was commenced in
08/2010. During treatment with AZA, three ON attacks
took place; one attack of myelitis and two of ON occurred
within 8 months despite treatment with MTX. At last
follow-up, the patient had VA of 0.1 in the left eye (and 1.0
in the right eye) but no paresis.
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Comment: This case – characterized by ON and
LETM, mild pleocytosis, no OCB, and a normal MRI at
onset – illustrates how similar the clinical presentation
in MOG-IgG-positive patients can be to that of AQP4-
IgG-positive NMO. In fact, a substantial proportion of
patients in this cohort met Wingerchuk’s 2006 criteria.
Of further note, 10 attacks occurred within only 85 months
in this patient. Overall, the disease took a relapsing course
in 80% of our patients. Moreover, as observed in many
cases, acute treatment with IVMP and PEX and long-term
immunosuppressive treatment were both only partially ef-
fective, resulting in a poor clinical outcome with func-
tional blindness in one eye at last follow-up.
Case 2 – Recurring LETM and IVMP-refractory ON in a
young girl, complete recovery after PEX. This young Cauca-
sian woman experienced a first attack of myelitis in 06/
2012 at age 17 with hypesthesia ascending from both feet
to level T4, followed by predominantly left-sided parapar-
esis and urinary incontinence. Spinal MRI in 08/2012 dem-
onstrated an LETM lesion extending from T3 to T6 with
Gd enhancement (no swelling or necrosis documented).
CSF WCC, OCB, QIgG, and total protein were normal.
After IVMP (5 × 1000 mg) symptoms remitted except for a
mild foot flexor paresis. AQP4 antibodies were negative.
A first relapse of myelitis occurred 1 year later, leading
to hemihypesthesia predominantly of the left arm and
torso. No MRI was performed. OCB were again negative.
5 × 1000 mg IVMP resulted in only partial recovery (EDSS
in remission 3.0). AQP4-IgG was again absent, but MOG-
IgG, which had not been previously tested, were positive.
In 07/2014, she suffered a first episode of unilateral ON
with painful eye movement, blurred vision, and a small
scotoma. VEP demonstrated prolonged P100 latency (am-
plitudes not reported). IVMP (5 × 1000 mg) resulted in
transient full recovery. However, after just 2 weeks symp-
toms flared up again, with similar VEP results but an
enlarged scotoma. Again, symptoms remitted completely
after treatment with IVMP (3 x 2000 mg), only to recur
after another 2 weeks. In between the first and second re-
flare, thrombosis in the patient’s superior sagittal sinus
occurred, most likely linked to extensive cortisone pulse
therapy. This was associated with two symptomatic epi-
leptic seizures probably due to focal edema. The second
re-flare was therefore treated with five cycles of PEX,
which resulted in complete remission. While VEP showed
a prolonged P100 latency (140 ms) in the affected eye dur-
ing relapse, VEP were normal at last follow-up in 03/2015.
Comment: As in patient 1, the disease took a severe,
recurring course, though in this case final outcome was
good. Of particular note, IVMP was effective during the
first attack but not or only partially during subsequent
attacks. Flare-ups after initial response to IVMP were
noted in several other patients, too. In this case, only
therapy escalation to PEX resolved the patient’s attack-
related symptoms. The occurrence of sinus thrombosis
with brain edema and seizures illustrates the risks of ex-
tensive cortisone pulse therapy.
Case 3 – Simultaneous bilateral ON and LETM in a
patient with rheumatoid arthritis; recurrent myelitis;
complete recovery. A 48-year-old woman with an 18-
month history of suspected seronegative RA, which had
been treated with oral MTX 15 mg per week starting in
March 2009, developed bilateral pain on eye movement
and severe visual loss in March 2010. Her personal and
family history was otherwise unremarkable. A few days
later, she additionally developed bilateral weakness of her
legs which progressed to severe tetraparesis. Furthermore,
she developed numbness of her trunk and legs starting at
level T3, severe disturbances of micturition (residual urine
400 mL) and defecation, and severe back pain which was
pronounced on head movement. Spinal MRI in an exter-
nal hospital showed an LETM lesion extending from C2
to T4. Cranial MRI showed no inflammatory lesions but
an old right-sided anterior infarction. A detailed search for
sources of embolism was negative. CSF analysis revealed
73 leukocytes/μl and moderate blood-CSF barrier dys-
function, while OCB were negative. Both vasculitis screen-
ing including antiphospholipid antibodies and AQP4
antibodies were repeatedly negative, as were extensive
infectiological investigations. The symptoms gradually im-
proved during initial intravenous treatment with ceftriax-
one, ampicillin, and aciclovir. Subsequent high-dose
intravenous steroid pulse therapy over 5 days accelerated
the remission of symptoms. When the patient first pre-
sented to our department 3 weeks after her symptoms had
started, vision had normalized and walking was already
possible without assistance. VEP amplitudes were reduced
bilaterally and the P100 latency was slightly prolonged on
the left side (121 ms). Tibialis SSEP were normal and
MEP to the tibial anterior muscles showed bilateral slight
prolongation of the central conduction time. The patient
continued MTX treatment. In August 2010, a detailed
neurological examination was unremarkable apart from
mild proximal paresis of her right leg, not to be explained
by the old anterior infarction on the same side. VEP, SSEP,
and MEP were normal. The patient was then seen at half-
yearly, later yearly intervals without developing further
symptoms until September 2013, when she presented with
acute painful numbness of her legs and lower trunk start-
ing at level T10 and a positive Lhermitte’s sign. Cervi-
cothoracic and cranial MRI did not show new or
enhancing lesions. CSF analysis revealed 17/mm3 leuko-
cytes and no evidence of a disturbed blood-CSF barrier
function; isoelectric focusing again did not show CSF-
specific OCB. Somatosensory and visual evoked potentials
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were normal. High-dose corticosteroid pulse therapy in-
duced full remission of the symptoms. Cranial MRI in 07/
2015 still did not show inflammatory lesions; cervicothor-
acic MRI in 08/2015 was unchanged. The patient was last
seen in 08/2015 without having developed further new
symptoms. She still continues treatment with MTX.
Comment: This patient’s initial presentation with sim-
ultaneous LETM and bilateral ON was considered typ-
ical of NMO for many decades. However, recent studies
have demonstrated that AQP4-IgG-positive NMO starts
with unilateral ON in the majority of cases; by contrast,
simultaneous ON and myelitis as well as bilateral ON at
onset have been found to be more common among
‘seronegative’ patients with NMO [34]. In the present
study, the disease started with simultaneous ON and
myelitis (with or without brainstem involvement) in 10%,
and the initial attack affected both eyes in 41% of all
patients with ON at onset, which corresponded to 30% of
all patients. Both the severity of the patient’s presenting
symptoms and the promptness as well as the nearly
complete remission observed in this case are remarkable.
Of particular interest, the patient’s first relapse occurred
while on treatment wth MTX for RA. In total, two attacks
occurred within 6 years of MTX treatment. Relatively low
relapse rates under treatment with MTX were also ob-
served in cases 3, 6, and 13 described here as well as in
cases 6 and 12 in part 3 of this series [31].
Case 4 – Simultaneous myelitis and bilateral ON with
complete recovery in a child. This 10-year-old Caucasian
girl experienced back pain and, within 10 days, developed
intention tremor of the upper extremities and complete
urinary retention. Neurological examination showed brisk
knee jerks without Babinski’s sign and urinary retention,
but was otherwise unremarkable. While cranial MRI was
normal, axial spinal cord imaging showed two small, non-
contrast-enhancing T2-hyperintense lesions in the cervical
cord with normal signal in the remaining spinal cord in-
cluding the conus. Ophthalmological assessment revealed
mild bilateral ON with impaired color perception and mild
papilledema of the left eye and slightly delayed P100 laten-
cies elicited from both eyes. CSF analysis disclosed 179
cells/μl with a high proportion of neutrophil (69%) and eo-
sinophil granulocytes, mild blood-CSF barrier dysfunction,
marginal intrathecal IgM synthesis, and CSF-restricted
OCB. Serology and PCR testing ruled out infection with
herpes simplex type 1, type 2, and type 6, varicella zoster
virus, enterovirus, arbovirus, Borrelia burgdorferi, and
Treponema pallidum. CSF cultures for bacterial microor-
ganisms were also negative. The serum tested negative for
AQP4-IgG, ANA, and ANCA. CRP was normal. MOG-
IgG was present at a titer of Treatment included short-
term antibiotics (ceftriaxone) followed by a 5-day pulse of
high-dose IVMP and prompted rapid resolution of symp-
toms. At last follow-up 26 months after onset the patient
did not report any residual symptoms; P100 latencies elic-
ited from both eyes were slightly delayed.
Comment: This case – together with cases 8 and 12 as
well as case 6 in part 3 of this series [31] – highlights that
MOG-IgG-related NMO may begin as early as in child-
hood or adolescence. As in case 3, the patient presented
with bilateral ON at onset and with simultaneous myelitis
and ON, two presentations that were previously shown to
be more common in AQP4-IgG-negative patients with
NMO [34]. Of note, the patient’s spinal cord lesions did
not extend over three or more vertebral segments. ‘Non-
longitudinally extensive’ lesions have recently been
described in two independent studies [34, 93] also in pa-
tients with AQP4-IgG-positive NMO; accordingly, LETM
lesions are no longer listed among the new, revised 2015
criteria for AQP4-IgG-positive NMOSD [29]. It is of inter-
est that mixed but predominantly neutrophilic pleocytosis
was present in this patient; CSF neutrophils were also
noted in 21 other patients with CSF pleocytosis and avail-
able data. Neutrophil granulocytes were shown to be
present also in around 50% of CSF samples in AQP4-
IgG-positive NMOSD during acute attacks [76].
Case 5 – Recurrent ON and purely sensory myelitis;
good recovery. This Caucasian man developed unilateral
ON at age 22 with complete recovery after high-dose
IVMP therapy. Lumbar puncture (LP) revealed CSF
pleocytosis (128 white cells/μl) and blood-CSF barrier
dysfunction. Brain MRI was normal except for optic
nerve swelling and Gd enhancement. VEP demonstrated
a delayed P100 latency but normal amplitudes. A second
ON attack occurred 10 months later but symptoms
again remitted completely following IVMP therapy. Over
the following 117 months, two more attacks of unilateral
ON with complete or almost complete recovery after
IVMP occurred, and one attack of myelitis with purely
sensory symptoms (including pain/dysesthesia) and blad-
der bowel dysfunction. Spinal cord MRI showed a short
lesion (one vertebral segment) without swelling or Gd
enhancement. IVMP treatment resulted in partial recov-
ery. Serum AQP4-IgG was negative, but MOG-IgG was de-
tected at a serum titer of 1:1280. At last follow-up, an EDSS
of 1.5 and normal VA was documented. No relapses have
occurred so far under treatment with rituximab, which was
commenced 2 months before the time of writing.
Comment: This case again illustrates that lesions in
MOG-IgG-positive myelitis are not always longitudinally
extensive and often exclusively cause sensory symptoms,
including pain and dysesthesia. Of note, the latter symp-
toms were the most common manifestations of myelitis
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in this cohort, having being present in around 70% of
all patients at least once.
II. MOG-IgG-positive NMO with brain involvement
Case 6 – LETM and 13 attacks of ON resulting in unilat-
eral blindness; white matter and callosal lesions. This
Caucasian woman had a first, left-sided attack of ON at age
47, with visual loss and retro-orbital pain. MRI showed a
longitudinally extensive Gd-enhancing optic nerve lesion
on the left side and a clinically inapparent short, Gd-
enhancing lesion in the posterior part of the prechias-
matic segment of the optic nerve which extended into
the optic chiasm. Symptoms completely remitted fol-
lowing high-dose IVMP treatment. Within 4 months
she developed transverse myelitis with thoracic pain,
sensory impairment of the abdomen and legs, and urin-
ary incontinence along with blurred vision affecting the
other, previously clinically unaffected eye, yet retained
high-contrast VA. Spinal MRI revealed two T2 hyperin-
tensities in the thoracic cord; one of these lesions
extended over three spinal segments and was accom-
panied by marked cord swelling and intense contrast
enhancement. Cranial MRI showed several non-Gd-
enhancing T2-hyperintense lesions in the subcortical
supratentorial white matter not involving the corpus callo-
sum. On neurophysiological testing, tibial nerve SSEPs had
normal latencies, VEP amplitudes were bilaterally reduced,
and P100 latencies were delayed on the left side. The CSF
disclosed 14 cells/μl (mostly lymphocytes with a small
number of neutrophils) and a normal protein profile with-
out blood-CSF barrier dysfunction and no CSF-restricted
oligoclonal IgG bands. The serum tested negative for
ANA, anti-ds-DNA-Ab, extractable nuclear antigens (ENA),
ANCA, and anti-phospholipid Ab; complement components
C3 and C4 were also not altered. High-dose IVMP treatment
followed by oral tapering of corticosteroids prompted almost
complete recovery of clinical symptoms with mild
dysesthesia and restlessness of the lower extremities.
Over the following 12 years, the patient experienced
12 further attacks of mostly unilateral ON, which
emerged at a frequency of once or twice per year and
were not affected by various long-term immune therap-
ies: 2 of the 12 relapses occurred under treatment with
i.m. IFN-beta-1a (1 and 4 months after first injection), 1
under s.c. IFN-beta-1a (less than 2 months after first in-
jection), 1 under s.c. IFN-beta-1b (after 2 months), none
under GLAT (6 months), and 1 during a short course of
AZA (4 months; no cotreatment with oral steroids).
Three PEX cycles (3-5 exchanges each) could also not
prevent bilateral deterioration of VA due to recurrent
ON with almost complete unilateral blindness and se-
vere contralateral visual loss (0.4 on last follow-up). Of
note, two relapses of ON occurred a few weeks after the
first and the second infusion of rituximab, respectively.
A further relapse of ON took place 12 months after initi-
ation of rituximab therapy and thus probably after re-
constitution of B cells. Treatment with IFN-beta-1a,
IFN-beta-1b, and GLAT had to be stopped prematurely
because of leukopenia; AZA was stopped due to elevated
liver enzymes.
Some stabilization of ON frequency was achieved fol-
lowing prolonged therapy with MTX and long-term
maintenance treatment with oral corticosteroids (com-
bined with ciclosporin for a period of 7 months); the pa-
tient experienced only two further attacks of ON within
almost 7 years after implementation of these regimens.
Repeat MRI 2 years after the initial ON revealed nu-
merically stable brain lesions and complete regression of
cord hyperintensities; however, after another 2 years, the
brain lesion load had increased, with some lesions now
involving the corpus callosum and infratentorial white
matter tracts. Follow-up laboratory analysis revealed a
normal CSF cell count with mildly elevated neutrophils
(6%) and protein profile with negative OCB. Serology
for AQP4-Ab was negative.
Comment: This case once more illustrates that MOG-
IgG-positive NMO is not always a mild and monophasic
disease but can take a relapsing course with poor long-
term outcome. Here, the disease caused functional blind-
ness in one eye and marked visual loss in the other eye
despite IVMP therapy for acute attacks and various im-
munotherapies. Of particular note and similar to case 12
described below and case 5 in part 3 of this series [31],
INF-beta treatment was paralled by several relapses. By
contrast, long-term treatment with MTX in combination
with oral steroids was followed by significant stabilization.
Case 7 – Recurrent ON and pregnancy-related LETM
with permanent functional blindness in one eye; white
matter lesions. This female Caucasian patient developed
a first episode of unilateral ON in 2005 at age 31 with
painful eye movement and blurred vision making read-
ing impossible. Several relapses of unilateral ON oc-
curred up to 2013, all of which responded well to IVMP
(5 × 1000 mg) with good partial or full remission of VA.
In 04/2013, at which time she was 6 weeks pregnant, she
developed numbness of both hands, later accompanied
by intense pain of her right arm and shoulder. MRI in
05/2013 revealed an LETM lesion in the cervical spinal
cord extending over five vertebral segments. In 12/2013,
i.e., only a few weeks after delivery, severe bilateral ON
occurred, starting in the left eye and shortly afterwards
affecting the right eye. Treatment with IVMP (3 ×
1000 mg) and therapy escalation with 2000 mg IVMP
2 weeks later did not result in any significant improve-
ment of the patient’s VA (left eye 0.025 in 02/2014). Fol-
lowing the start of rituximab in 02/2014, very slow
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subjective improvement of visual function was noted.
AQP4-IgG and a broad panel of other anti-neural auto-
antibodies were negative. MOG-IgG were positive in
two samples. Brain MRI was normal at onset but showed
inflammatory white matter lesions later. LP revealed
pleocytosis (37 cells/μl) but no OCB.
Comment: Of particular note, two attacks in this patient
occurred during pregnancy or shortly after delivery, re-
spectively. Similarly, attacks occurred 1.5, 3 and 8 months
after delivery in case 12 in part 3 of this series [31] and in
cases 23 and 19 described below, respectively. One further
patient experienced at least two attacks during pregnancy
(see case 13 in part 3 [31]). An increase in relapses post
partum has been reported in MS [108], and a negative in-
fluence of pregnancy on the disease course has been sug-
gested in NMO as well [85, 86]. On the other hand,
disease onset preceded pregnancy by more than 8 years in
our patient and several relapses had occurred before the
first pregnancy-related attack. A simple coincidence thus
cannot be ruled out. Note the poor outcome in this pa-
tient: While IVMP was initially effective, both high- and
ultra-high-dose IVMP therapy failed to restore vision
later on, resulting in permanent visual loss in the left
eye.
Case 8 – LETM and recurrent bilateral ON with transi-
ent blindness but full recovery in a young boy, ventricular
lesion. This young Caucasian male patient first pre-
sented in September 2006 at age 12 with an attack of
bilateral ON with blurred vision. The symptoms remit-
ted partially after IVMP pulse therapy.
Six weeks later, he developed headaches and tetrapar-
esis. MRI showed a supratentorial lesion at the anterior
horn of the right lateral ventricle and a cervical lesion
extending from C2 to C6 level with Gd enhancement
and swelling. ADEM was suspected. Extensive laboratory
examinations did not reveal any infectious or rheumato-
logical cause. Family history was negative for relevant
autoimmune diseases. LP showed a normal CSF WCC,
normal CSF protein, glucose, and lactate levels, and
negative OCB. After IVMP therapy, vision and muscle
strength returned to normal.
The third attack occurred in 03/2012 with almost
complete loss of vision of the right eye. LP revealed a
normal CSF WCC, normal CSF protein concentration,
and negative OCB. AQP4 antibodies were negative.
Cerebral MRI showed Gd enhancement of the optic chi-
asm. VEP revealed bilaterally delayed P100 latencies with
normal amplitudes. OCT demonstrated bilateral tem-
poral thinning of the retinal nerve fiber layer (RFNL).
No clinical signs or symptoms of myelitis were present,
but MRI showed a T2 lesion at C3, spanning around one
and a half vertebral segments, as well as diffuse lesions
extending from level C4 to C7 and from level T7 to T9
with Gd enhancement and swelling. After treatment
with IVMP, symptoms remitted completely. MS with an
opticospinal focus or NMO was suspected and treatment
with GLAT was initiated.
Spinal cord MRI in 09/2013 showed remission of the
cervical lesions with a remaining small lesion at C2. At
last follow-up in 06/2015, after 36 months of treatment
with GLAT, the patient did not report any further clin-
ical relapses and had only mild clinical deficits (EDSS 1).
Comment: While bilateral ON and myelitis did not
occur strictly simultaneously in this patient, the interval
between the two events was just 6 weeks. Similarly, a very
short median time to first relapse (5 months) was found in
the total cohort. This suggests that patients presenting
with a first attack of MOG-IgG-positive ON or myelitis
should be closely monitored and treated early. The severe
symptoms noted during acute ON (almost complete
unilateral blindness) contrast remarkably with the
complete remission achieved after IVMP in this case. Note
the young age at onset in this and in three other patients
(cases 4 and 12 here and case 6 in part 3 of this article
series [31].
Case 9 – Bilateral ON and subsequent LETM with late
onset and only partial recovery, callosal lesions on MRI.
This Caucasian woman developed bilateral optic neuritis
in 11/2009 at age 64 with spontaneous complete remis-
sion within 6 weeks but subsequently prolonged P100 la-
tencies. From 01/2011, she complained of increasing
dysesthesia in both forearms and impaired ambulation.
Spinal MRI in 05/2011 showed two cervical contrast-
enhancing lesions. LP revealed identical OCB in CSF
and serum (mirror pattern) and a normal cell count.
AQP4 antibodies were negative. Except for ANA (1:160),
no other concomitant autoantibodies were detected.
Treatment with IVMP in 05/2011, 07/2011, and 09/2011
did not result in significant improvement of the still in-
creasing dysesthesia. In 10/2011, spinal MRI showed dif-
fuse hyperintensity ranging from C2 to C6 with Gd
enhancement. Cranial MRI revealed numerous non-
specific T2 hyperintensities considered to reflect micro-
vascular lesions due to a long history of hypertension. In
12/2011 MOG-IgG was tested for the first time and was
positive at a titer of 1:1280. After 11 courses of PEX (12/
2011 to 08/2013) and 29 months of treatment with AZA
(2 x 50 mg/day, from 01/2012) dysesthesia was still
present but not increasing anymore and no further
relapses had occurred at last follow-up (06/2014).
Follow-up MRI in 02/2013 showed, in addition to the
vascular lesions, callosal lesions compatible with focal
demyelination and residual discrete T2 hyperintensities
in the cervical spinal cord.
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Comment: As in 14 further cases, disease started with
bilateral ON in this patient. While bilateral ON had
traditionally been considered typical for NMO, it was
recently shown to be in fact more frequent in AQP4-
IgG-negative than in AQP4-IgG-positive patients with
NMOSD at disease onset [34]. Of particular interest,
LETM was purely sensory, characterized by excruciating
dysesthesia, took a protracted or even progressive
course, and did not respond to repeat IVMP treatments
over a period of 12 months; only PEX and subsequent
immunosuppression brought some relief. Surprisingly,
15/19 (78.9%) patients in this cohort reported at least
one occurrence of dysesthesia or pain during acute mye-
litis attacks. Dysesthesia and pain are also common
symptoms in AQP4-IgG-positive NMO and are the only
symptom in some patients [34]. Both MOG-IgG- and
AQP4-IgG-related EM should be considered in the dif-
ferential diagnosis of patients presenting with purely
sensory symptoms compatible with myelitis.
Case 10 – Recurrent attacks of ON and myelitis with
good partial recovery; subcortical and callosal lesions. This
Asian male patient developed bilateral optic neuritis (VA
not documented) in 12/2006 at the age of 35. CSF exam-
ination showed a normal cell count and normal protein,
glucose, and lactate levels with negative OCB. Brain
MRI showed Gd enhancement of both optic nerves, one
subcortical lesion in the left cerebral hemisphere, and
one lesion in the corpus callosum. Spinal cord MRI was
not performed at that time. After IVMP pulse therapy
complete remission was documented. Extensive labora-
tory work-up did not reveal any infectious or rheumato-
logical cause of the symptoms.
A second attack occurred in 10/2007 with clinical
symptoms of myelitis (paraparesis, urinary retention,
and tingling sensation in the lower extremities). LP re-
vealed an increased cell count (197 cells/μl) with a nor-
mal protein level and negative OCB. Spinal MRI
showed multifocal myelitis of the upper cervical and
thoracic segments (C3-C4, T3-T4) with patchy gadolin-
ium enhancement. After IVMP pulse therapy there was
only partial remission and slight unsteadiness of gait
remained. MS with an opticospinal focus or neuromy-
elitis optica was suspected. Treatment with AZA 2 mg/
kg (150 mg/day) was initiated and was continued until
07/2008 when treatment was stopped due to clinical
stabilization.
The third attack occurred in 03/2010 with unilateral
optic neuritis. MRI showed Gd enhancement of the right
optic nerve and the previously known T2 lesions with
patchy gadolinium enhancement. AQP4 antibodies were
tested 4 times during this period and were always nega-
tive. Complete remission after IVMP pulse treatment
was achieved.
After a fourth attack in 08/2010 with tingling sensa-
tion of the lower extremities which was treated with 5 g
IVMP with complete remission, treatment with AZA
was reinitiated directly after discontinuation of IVMP.
Beginning in 01/2011 (i.e., still within the latency period
of AZA) another relapse of myelitis with tingling sensation
of the lower extremities and of the right hand (EDSS 2)
was treated successfully with IVMP. A VEP examination
performed at that time revealed delayed P100 latencies
bilaterally with normal amplitudes. OCT showed bilateral
thinning of the RFNL. Cerebral and spinal MRI did not
show any disease activity. AZA was increased to 200 mg/
day and later continued at 150 mg/day. The last MRI of
the head and spinal cord was performed in 04/2014 and
showed no disease activity. The patient was still relapse-
free at last follow-up in 04/2015 with an EDSS of 2.5. In
total, this patient has experienced five attacks, comprising
two attacks of ON (1 × bilateral) and three of myelitis.
Comment: First, the presence of callosal brain lesions
noted in this patient and in others in our study (see
cases 6 and 9 here and cases 3 and 8 in part 3 [31]) ren-
ders the radiological differential diagnosis of MOG-IgG-
positive EM and classical MS more challenging. Callosal
lesions have also been observed in AQP4-IgG-positive
NMO, where they are typically long (half of the length
of the corpus callosum or greater), diffuse, heteroge-
neous, or edematous [29, 109]. In the present cohort, a
longitudinally extensive callosal lesion was noted only in
a single patient (see case 3 in part 3 of this series [31]).
Second, as a result of ON, RFNL thinning as detected by
OCT was present in this as well as in several other pa-
tients. Similar findings have previously been reported in
AQP4-IgG-positive patients [110, 111]. A detailed OCT
analysis of 16 patients with MOG-IgG-positive ON can
be found in part 4 of this article series [32].
III. MOG-IgG-positive recurrent ON
Case 11 – Three attacks of ON; no brain lesions;
functional blindness in the left eye. A 53-year-old woman
first noted reduced vision and pain on moving the right
eye in 05/2011. Clinical examination demonstrated a VA
of 0.1 in the right eye and 1.0 in the left eye, as well as
color desaturation and a relative afferent pupillary defect
of the right eye. Cranial MRI showed right optic neuritis,
but no parenchymal brain lesions. VEP were slightly de-
layed in the right eye, but amplitudes were preserved.
CSF analysis was normal; in particular, there were no
CSF-specific OCB. The patient was treated with high-
dose IVMP (2 g/d for 3 days), which resulted in im-
provement of symptoms. However, about 3 weeks later
vision in the right eye deteriorated again.
In 11/2011, she also noted reduced vision in the left eye.
She was again administered several courses of IVMP,
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which did not improve VA, so that she was subsequently
treated with four courses of IA. This was associated with
almost complete recovery over the next 3 years.
At the end of 11/2014 she again noted reduced VA in
the left eye. A cranial MRI performed in 12/2014 showed
a left optic neuritis with contrast enhancement as well as
hyperintensities in the right optic nerve without contrast
enhancement, but no further cerebral lesions. She was
again treated with IVMP and four courses of IA, which re-
sulted in only incomplete recovery. In 03/2015, when her
VA was finger counting in the left and 0.2 in the right eye,
she was admitted to our department. She was tested for
serum antibodies to MOG, which were positive both in a
live-cell and in a fixed-cell CBA (determined after IA). She
was treated with IVMP, five courses of PEX, and rituximab
(2 × 1000 mg). However, VA recovered only slightly. At
the last follow-up in 05/2015 her vision was 0.2-0.3 in the
right and 0.02 in the left eye.
Comment: This case, together with cases 12-18, dem-
onstrates that MOG-IgG-associated ON is not always a
monophasic disease but frequently follows a relapsing
course. In fact, recurrent ON was noted in 65% of all
patients with isolated ON in the present study. More-
over, the disease took a very severe course with partly
therapy-refractory attacks, leading to permanent func-
tional blindness in one eye and substantial loss of VA in
the other eye. As in other patients in this series, high-
dose and even ultra-high-dose IVMP treatment
improved the symptoms only transiently or not at all.
Although IA was initially effective, it could not restore
vision when used to treat a subsequent relapse. While
the reason for that discrepancy is unknown, the rela-
tively long time (6 weeks) between attack onset and IA
might have played a role. Alternatively, IA as well as
PEX might not result in a sufficient decrease in MOG-
IgG titers in some patients if not repeated long enough;
finally, other pathomechanisms than antibody-related
ones, e.g., T cells, might have been involved.
Case 12 – Recurrent ON in a child; no brain lesions;
severe permanent visual loss. This Caucasian girl experi-
enced a first episode of ON in 04/2001 at age 6; this at-
tack was bilateral (OD> >OS) with papilledema. VEP
showed prolonged P100 latencies. LP demonstrated mild
CSF pleocytosis (7 leukocytes/μl). Brain MRI was nor-
mal. Symptoms remitted spontaneously. Two years later
(04/2003) a second attack of ON occurred, affecting the
right eye. Symptoms improved with IVMP. A third at-
tack of ON, again of the right eye, developed 11 months
later in 03/2004. CSF was normal. A serum sample
drawn in 2004 that was later retrospectively tested was
positive for MOG-IgG. When right-sided ON recurred
in 08/2008, temporal pallor was noted on fundoscopy
bilaterally. In 2009, ocular myositis was suspected, but
no additional information is available. In 01/2013 an-
other attack of unilateral ON occurred, associated with
contrast enhancement of the right optic nerve; symp-
toms improved with IVMP. In 04/2013, the patient was
started on IFN beta-1a s.c. However, she experienced
two more attacks of right-sided ON in 10/2013 and 03/
2014, leading to the discontinuation of IFN-beta treat-
ment; both relapses improved after IVMP. MRI still did
not show any brain lesions in 10/2013, i.e., 12 years after
onset. VA was 0.4 in the right and 0.8 in the left eye
at that time. AQP4-IgG antibodies were negative. An
OCT examination in 04/2014 showed massive thin-
ning of the RNFL in both eyes (OD > OS). In 07/2014
and again in 01/2015, the patient received two doses of ri-
tuximab (2 × 1000 mg, 2 weeks apart). At last follow-up
in 03/2015 no further relapses had occurred.
Comment: This is one of the youngest Caucasian pa-
tients with MOG-IgG positive ON reported thus far.
MOG-IgG autoimmunity is an important differential
diagnosis in pediatric patients presenting with NMOSD
and other forms of CNS inflammation of unknown cause
[107, 112, 113]. The patient’s relapsing disease course
confirms that MOG-IgG in pediatric patients with ON is
not, as originally thought, limited to monophasic cases
[11–13]. Of particular note, the disease has been re-
stricted to the optic nerves in this patient for more than
a decade, both clinically and radiologically. As in two
other patients (case 6 here and case 4 in part 3 of this
series [31]), treatment with IFN-beta was not effective in
preventing relapses.
Case 13 – Recurrent ON with late onset; no inflammatory
brain lesions; permanent unilateral blindness. This Caucasian
woman developed severe bilateral optic neuritis in 12/2003
at age 66 following a gastrointestinal infection with
positive Yersinia serology (species not specified). VA at
nadir was 0.1 in both eyes. VEP showed no response of
the right eye and was delayed on the left side. Symp-
toms partly responded to IVMP and oral prednisolone.
Brain MRI was normal except for numerous vasculopathic
lesions due to decades of hypertension. LP showed CSF
pleocytosis (80 cells/μl) but no OCB.
The patient was treated with AZA (150 mg/d) and oral
steroids from 03/2004 to 11/2004. However, one ON re-
lapse in the right eye occurred at the end of 04/2004
(with a flare-up in mid-05/2004) and a second in 10/
2004 after tapering prednisolone to below 10 mg/day.
Symptoms did not substantially improve despite several
courses of IVMP (VA 1/35). A follow-up CSF examin-
ation performed at that time was normal.
In 11/2004, treatment was switched to MTX (15 mg/
week). In 01/2006, the patient experienced another
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attack of unilateral ON, which led to blindness of the
right eye. The patient declined IVMP, and symptoms did
not improve spontaneously.
No further relapses have occurred under treatment
with MTX since then. In 06/2013 VA of 0 on the right
and 1.0 on the left side was documented. At last follow-
up, in January 2016, the patient was still on MTX
(2.5 mg/day). She never experienced any signs or symp-
toms of myelitis; spinal MRI (11/2004) was normal.
Slightly elevated ANA (1:80) were documented on one
occasion, but she has no coexisting autoimmune
disorders.
Comment: This case is interesting for several reasons:
First, disease started after an acute infection, as also seen
in at least 10 other patients in our series. Infections have
also been reported as a trigger of acute attacks in AQP4-
IgG-positive NMOSD [34] and in classic MS [114]. Sec-
ond, tapering of steroids resulted in recurrence of the
patient’s symptoms. Similarly, withdrawal of steroids or
reductions in steroid dosage resulted in flare-ups in 20
further patients in our series. Third, disease resulted in
permanent blindness in one eye in this patient. Similarly, a
decline in VA ≤0.5 occurred in 85% of our patients during
relapse and severe visual impairment or functional blind-
ness was present in 37% at last follow-up. This underlines
that the notion of MOG-IgG-associated ON being gener-
ally mild is incorrect. Fourth, while two attacks occurred
under treatment with AZA (and cotreatment with oral
steroids) within a period of 9 months in this patient, only
one – albeit very severe – relapse occurred under MTX
over a period of 10 years. The favorable disease course ob-
served in this and in other MTX-treated patients in this
study (see cases 3, 6, and 13 here and cases 6 and 12 in part
3 of this article series [31]) warrants further investigations
into the potential efficacy of MTX in MOG-IgG-related
autoimmunity.
Case 14 – Recurrent ON starting at age 28; no brain
lesions; permanent functional blindness of the left eye.
This patient presented with unilateral ON (VA OD 1/
35) in 05/2009 at age 28. Symptoms improved following
high-dose IVMP (3 × 1 g), but recurred shortly thereafter
(VA OD 1/35) and only partly responded to a second
IVMP (3 × 1 g) cycle (VA 0.2). Brain MRI was normal.
Five months after onset, the patient developed left-
sided ON, which fully responded to IVMP. Brain MRI
was again normal, except for enhancement of the left
optic nerve and edematous thickening of the right optic
nerve. VEP examination revealed bilaterally prolonged
P100 latencies (OD >OS) and reduced amplitudes.
Another attack of ON, on the left side, occurred
2 months later with severe visual loss (VA 0.1). Fundos-
copy revealed mild papilledema. IVMP and 10 plasma ex-
changes resulted in partial improvement. The patient was
started on AZA 100 mg/day in 10/2009 with 6 months
cotreatment with oral steroids. In 02/2012, she experienced
another relapse of ON, which partially responded to IVMP.
The patient had no other immune disorders except for pol-
linosis. LP had revealed mild pleocytosis (14 cells/μl) but
no CSF-restricted OCB and no blood-CSF barrier dysfunc-
tion. A serum sample obtained 2 weeks after IVMP therapy
was positive for MOG-IgG at a titer of 1:160 in the live-cell
assay. MOG-IgG-seropositivity was confirmed in the fixed-
cell assay. AQP4-IgG was negative. At last follow-up VA of
0.1 in the left eye was documented.
Comment: As in many patients in this series, the first
high-dose IVMP cycle led only to transient remission of
symptoms in this case; moreover, only partial recovery
was achieved after a second cycle applied for the same at-
tack as well as during two later attacks. The observation
of many cases of partial or complete IVMP failure in this
series suggests that additional treatment options should
be considered in MOG-IgG-positive patients presenting
with acute ON or myelitis. It is unknown why IVMP was
effective during some attacks, but not all, in this and other
patients. However, timing issues and differences in anti-
body titers, other immunological parameters (e.g., T cell
activation), IVMP dosage, and previous or concomitant
treatments might all play a role. Note the poor outcome
in this case. Functional blindness in at least one eye was
also noted in 9 additional patients at last follow-up.
Case 15 – Three attacks of ON; no brain lesions; full
recovery. This 25-year-old woman presented in 10/2010
with bilateral ON accompanied by visual loss and retro-
orbital pain on eye movement. Fundoscopy revealed optic
papillitis in both eyes. Except for a marginal difference in
biceps tendon reflexes the neurological examination was
normal. LP showed normal intracranial pressure, slight
pleocytosis (6 cells/μl), normal CSF total protein, glu-
cose, and lactate levels, and negative OCB. VEP were
lost in both eyes. Cerebral MRI was normal including
the optic nerves. Spinal MRI was not performed at that
time. AQP4 antibodies were negative as were extensive
infectious and rheumatological laboratory diagnostics.
After IVMP therapy (1 g/d for 5 days), the patient com-
pletely recovered within 2 weeks.
In 11/2010, 4 weeks after onset of the first symptoms, a
second attack occurred with complete visual loss in the
right eye and a decrease in VA to 60% in the left eye.
Ophthalmological examination revealed bilateral optic
papillitis. VEP in both eyes could not be elicited. IVMP
pulse therapy (2 g for 5 days), followed by oral reduction
over 4 weeks, led to rapid and complete recovery.
The patient was clinically stable without any mainten-
ance therapy until 11/2014, when she developed a third at-
tack of ON with a decrease in VA of the right eye to 40%
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and papillitis of the right optic nerve. The neurological
examination was normal. Two cycles of IVMP pulse ther-
apy (1 g/d) for 3 and 5 days, respectively, resulted in
complete remission after 2 weeks. In 12/2014 a second
brain MRI and a first spinal cord MRI were performed,
each with normal findings. SSEP were normal as well.
MOG antibodies were first determined in 03/2015 and
were positive. AQP4 antibodies were still negative. At
that point the patient was free of symptoms and VEP
were normal in both eyes. The patient rejected the idea
of commencing any long-term immunosuppressive
treatment.
Comment: Despite recurrent disease and severe acute
visual impairment with transient blindness and loss of
VEP, this patient recovered completely from all attacks
following high-dose IVMP (and subsequent oral tapering
for one attack). Remarkably, there were no clinical,
radiological, or electrophysiological signs of myelitis,
brain, brainstem, or cerebellar involvement 3 years after
onset; similarly, there was no evidence for spatial dis-
semination at last follow-up in around a quarter of all
MOG-IgG-positive patients in this study.
Case 16 – Recurrent ON; no brain lesions; significant vis-
ual loss in both eyes. This patient had a first attack of ON
at age 58. At last follow-up, 86 months after onset, eight
unilateral ON attacks alternately affecting the left and the
right eye (never simultaneously bilateral) had occurred
but no brain or spinal cord involvement was noted.
MOG-IgG were detected retrospectively in a stored
sample taken under treatment with oral steroids. VA was
0.4 in the left and 0.5 in the right eye at the last follow-up
visit (during remission). There was no relevant co-
morbidity, including no concomitant autoimmune dis-
eases, and no autoantibodies other than MOG-IgG
were detected.
Comment: This case, which is characterized by high
disease activity (ARR 1.2) and poor long-term outcome,
again illustrates that MOG-IgG-positive ON is not al-
ways a monophasic and mild disease. Disease activity
varied substantially among untreated patients with
isolated ON. While this patient experienced eight ON
attacks within just 86 months, no relapse occurred
within 72 months in case 22. This renders decisions
about long-term treatment difficult, all the more as
reliable long-term prognostic markers are lacking.
However, with more than 60% of all patients with
isolated ON having developed relapses and around
two thirds of those with relapses having been func-
tionally blind or otherwise severely impaired in at
least one eye at last follow-up, long-term treatment
should be considered in most cases.
Case 17 - Recurrent bilateral ON; transient unilateral
blindness; full recovery. This Caucasian woman developed
a first episode of bilateral ON at the age of 50, presenting
with bi-frontal headache, painful eye movements, and
blurred vision. VA was 0.5 in the right and 0.8 in the left
eye at first clinical presentation. VEP displayed a
prolonged P100 latency (right > left). Brain MRI
showed contrast agent enhancement of both optic
nerves but was otherwise normal, as was spinal cord
MRI. CSF revealed mild pleocytosis (21/μl, lympho-
monocytic), elevated total protein (929 mg/l), no OCB,
and a normal IgG CSF/serum ratio. No other laboratory
abnormalities were noted (ANA, ANCA, cardiolipin,
beta2-glycoprotein, ACE, soluble IL2R, borreliosis, syph-
ilis). The patient’s medical history was unremarkable ex-
cept for arterial hypertension. Following high-dose IVMP,
VA initially improved to 0.7 right and 1.0 left; however, a
bilateral flare-up of ON occurred within 30 days, resulting
in a drop of VA to light perception on the right and 0.5 on
the left. The patient received five plasma exchanges which
resulted in full recovery.
Three months later another bilateral ON attack with a
large scotoma occurred. Full remission (bilateral VA 1.0)
was achieved with high-dose IVMP. A further 2.5 years
later (10/2012) the patient experienced a mild ON attack
with blurred vision but without a drop in VA in the right
eye. Following the patient’s preferences, no relapse treat-
ment was given and no preventive immunosuppressive
treatment was initiated. Re-testing for serum autoanti-
bodies was unremarkable (NMDA-IgA/IgG, amphiphysin,
CV2/CRMP5, Ma2/Ta, Ri, Yo, Hu, LGI1, CASPR2,
GABA-B receptors, AMPA receptors, GAD, MAG, c-
ANCA, p-ANCA, rheumatoid factor, ganglioside anti-
bodies) except for low-titer ANA (1:160). At last
follow-up (11/2015) VA was 1.0 in both eyes and no
further relapses had occurred.
Comment: Disease again affected exclusively the optic
nerves. The excellent long-term outcome despite large
scotoma and near-blindness during acute attacks is re-
markable. As in around 44% of all patients, IVMP was
only transiently effective when used to treat acute attacks;
PEX was required to achieve full remission but, of particu-
lar note, could prevent further relapses only for 3 months.
Case 18 – Recurrent ON with late onset; permanent
functional blindness; stabilization under rituximab. A
58-year-old woman with a history of hepatitis A two de-
cades previously developed amaurosis in the right eye and
headache in 04/2014. Clinical examination revealed a VA
of 1/100 in the right eye with global alteration of right vis-
ual field and delayed and reduced amplitude of P100 wave
at visual evoked potential (VEP). Brain MRI showed T2/
FLAIR hyperintensity of the right optic nerve with spotty
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post-contrast enhancement and non-specific subcortical
frontal hyperintense lesions. Spinal MRI and CSF were
normal. Routine laboratory examinations were normal ex-
cept for low-titer ANA (1:80). Despite treatment with
high-dose IVMP, almost no improvement was achieved
(VA 1/10). Two months later (06/2014) the patient devel-
oped left-sided ON. Treatment with oral steroids resulted
in only mild improvement (5-6/10). Two and four months
later (08/2014 and 10/2014), respectively, further ON at-
tacks affecting the left eye occurred; high-dose IVMP was
followed by almost full recovery of VA in this eye. At that
time, serum positivity to anti-MOG antibodies was de-
tected. In 10/2014 treatment with rituximab (2 ×
1000 mg, 2 weeks apart) and oral steroids was started
and was followed by further improvement of VA in the
left but not in the right eye. At a follow-up visit 1 year
after the last attack, VA was 9/10 on the left (with nor-
mal VEP) and 1/10 on the right. Of note, CD19 cells
were still undetectable 14 months after the first rituxi-
mab infusion in this patient.
Comment: While this patient almost completely re-
covered from three ON attacks in the left eye, no im-
provement had been achieved after the initial attack,
which had affected the right eye and had left the patient
functionally blind. This illustrates that the severity of
MOG-IgG-associated attacks varies substantially not
only between patients but also intraindividually. Studies
investigating risk factors for poor attack outcome in
MOG-IgG-positive patients are highly warranted.
IV. MOG-IgG-positive monophasic ON
Case 19 – Single episode of post-infectious bilateral ON
8 months post partum; no brain lesions; partial recovery.
A 30-year-old woman who was breastfeeding her 8-month-
old healthy daughter noticed bilateral blurred vision, pain
when moving the eyes, and moderate frontal headaches in
February 2011. During the weeks before symptom onset,
she had had common colds with mild fever. Her past med-
ical history was otherwise unremarkable. Ophthalmological
examination demonstrated reduced VA of the right (1/25)
more than of the left eye (0.5), reduced color vision in the
right eye, and papillitis of the right more than of the left
eye. Visual field examination revealed bilateral large centro-
cecal scotomas, again more prominent in the right eye. The
patient was admitted to our department, where the rest of
the neurological examination was normal. Cranial and or-
bital MRI demonstrated contrast enhancement in both
optic nerves, compatible with bilateral optic neuritis, but
no lesions in the brain parenchyma. Spinal MRI and chest
radiography were unremarkable. CSF analysis revealed a
mildly elevated total cell count of 12 white blood cells per
μl (reference range, <5/μl) with 88% lymphocytes and 12%
monocytes. CSF protein and lactate were normal and there
were no CSF-specific OCB. A complete blood count and
C-reactive protein were normal, as were microbiological
(Borrelia, Treponema pallidum, Toxoplasma) and viro-
logical tests (herpes simplex virus type 1 and 2, varicella
zoster virus). ANA were detectable at a titer of 1:320.
Screening for ENA, ANCA, and AQP4-IgG was negative.
However, antibodies to MOG were detected in the patient’s
serum at a titer of 1:1280. The patient was treated with
IVMP (1 g/day for 5 days). An ophthalmological follow-up
examination in August 2011 showed markedly improved
VA of the right (0.7-0.8) and left (0.7) eye. The visual field
defects had almost completely resolved. Funduscopy re-
vealed bilateral mild temporal disk pallor consistent with
mild partial optic atrophy.
Comment: This patient developed her first relapse in
the third trimester post partum. The first 9 months after
pregnancy have been previously identified as a risk
period for relapses both in AQP4-IgG-positive NMO
[85, 86, 115] and in MS [108]. However, systematic stud-
ies comparing ARRs before, during, and after pregnancy
in MOG-IgG-positive patients are still lacking. Of note,
the temporal association between the two events could
still be coincidental in the present case, all the more as
disease onset was also preceded by feverish infection.
Remarkably, almost complete recovery was achieved
despite substantial visual loss during an acute attack.
Case 20 – Protracted single episode of bilateral ON;
delayed SSP; no brain lesions; complete recovery. This
Caucasian man developed a first, bilateral ON at age 70
with severe vision loss (0.5 OD, 0.4 OS), papilledema,
scotoma, and delayed P100 latencies (but no or only
marginally reduced P100 amplitudes). Treatment with
high-dose IV prednisolone (1000 mg 3d) with oral taper-
ing resulted in marked but incomplete short-term recov-
ery with persisting contrast sensitivity impairment and
hazy vision. Within 4 weeks from onset of symptoms
bilateral visual loss (0.5 OD and OS) and scotoma re-
curred and improved gradually after a second course of
high-dose i.v. prednisolone (1000 mg 3 d) with oral ta-
pering and additional intravenous antibiotics (sobelin,
ceftriaxone). Brain MRI revealed slight perineural con-
trast enhancement around the left optic nerve and signs
of ethmoidal cell sinusitis, but was otherwise unremark-
able. While spinal MRI did not unequivocally reveal any
lesions, tibial nerve SSEP were bilaterally delayed (69 ms
on the right; only late components obtainable on the
left), suggesting possible subclinical myelitis. Median
nerve SSEP were normal except for a side difference in
latencies. Transcortical magnetic stimulation to the legs
was normal as well. CSF assessment revealed a normal
cell profile, mild blood-CSF barrier dysfunction, and no
OCB. AQP4-IgG-testing was negative. The patient had
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been diagnosed with hepatitis B more than 20 years before
onset of symptoms; however, Hbs, HBc-IgG, HCV-IgG,
and HBE were all negative at the time of ON, as were
ANA, ANCA, CRP and rheumatoid factor. Chest radiog-
raphy did not reveal evidence of sarcoidosis, and serum
ACE was normal. At repeated long-term follow-up visits
(most recently in 10/2010) complete recovery was con-
firmed with normal VA and no evidence of scotoma.
Comment: This case, alongside the pediatric cases re-
ported here, illustrates the broad variability in age of onset
in MOG-IgG-related disorders. A late onset (>60 years)
was also observed in two further patients (66 years in case
13; 64 years in case 9). While MOG-IgG were originally
described in pediatric patients with ADEM, these cases
demonstrate that MOG-IgG need to be considered also in
elderly patients presenting with a first attack of optic neur-
itis or myelitis. Moreover, this case is one of the few
monophasic ones, with no relapse more than 6 years after
onset. By contrast, disease followed a relapsing course in
80% of all MOG-IgG-positive patients in this cohort, irre-
spective of clinical presentation.
Case 21 – Single episode of unilateral ON; no brain
lesions; complete recovery. This man presented at age 53
with unilateral retrobulbar ON of the left eye (VA 0/10,
peripheral scotoma, intraorbital swelling, and Gd en-
hancement of the optic nerve with contrast enhance-
ment, VEP delayed and amplitudes reduced; right eye
normal). LP was unremarkable with 2 cells/μl, no OCB,
and normal CSF/serum ratios of IgG and albumin. MRI
revealed no extra-optic nerve brain lesions. MOG-IgG
were positive at a titer of 1:1280 prior to treatment.
Treatment with high-dose steroids resulted in marked
improvement (1 mg/d for 6 days) with complete recov-
ery after some months (VA 10/10). Electrophysiological
control examinations 7 and 18 months after onset
showed only a residual borderline delay in P100 latency
on the left side; brain MRI was still normal 25 months
after onset; and at last follow-up at month 75 no new
symptoms had occurred. The patient had a history of
poliomyelitis during childhood and of brucellosis
12 years prior to ON. Serum AQP4-IgG was absent, but
MOG-IgG was present at a titer of 1:1280.
Comment: The favorable attack outcome – with
complete recovery following IVMP treatment – and the
monophasic disease course – with no new symptoms
75 months after onset – once more illustrate the broad
variability in prognosis in MOG-IgG-positive ON.
Case 22 – Single episode of unilateral ON; no brain
lesions; persisting visual deficit. A 29-year-old man de-
veloped sudden loss of vision and reduced visual field in
the right eye. VA was initially 20/200 in the affected eye.
Unilateral ON was diagnosed. Brain MRI and intracra-
nial pressure were normal. CSF showed normal
leukocyte count, IgG index, and protein level, and no
OCB. AQP4-IgG was negative. At follow-up, persisting
visual loss (20/60) of the right eye was apparent. So far,
no further attacks have occurred. Of note, this patient
had psychiatric difficulties in the past (classified as
ADHD) and a previous history of central diabetes insipi-
dus of unknown cause with onset at age 7 years.
Comment: It remains unknown whether the patient’s
diabetes insipidus and psychiatric symptoms were
caused by CNS autoimmunity. Of note, however, psychi-
atric symptoms (psychomotor slowing, disorientation,
and impaired consciousness) were present in two further
patients in this series (described in detail in part 3 [31])
and occasionally occur also in AQP4-IgG-positive pa-
tients [116–118]. Central diabetes insipidus, which is
characterized by a lack of antidiuretic hormone (ADH)
in the brain, has been previously reported in a patient
with NMO but unknown AQP4-IgG and MOG-IgG ser-
ostatus [119], and several AQP4-IgG-positive NMOSD
patients with Schwartz-Bartter syndrome (also termed
syndrome of inappropriate ADH secretion) due to hypo-
thalamic lesions have been described over the past few
years [120–122].
Case 23 – Post-partum episode of ON; possible onset of
disease already at age 10; low- rather than high-contrast
VA affected. In 1995, at the age of 10 years, this Caucasian
patient had suffered from a self-reported “Borrelia-in-
duced meningitis” with headache, diplopia, and bulbar
movement pain, with one recurrence 1.5 years later. More
than 18 years later, in 07/2015, and 3 months after delivery
of her first child, the then 30-year-old woman developed
subacute retrobulbar pain and frontal headache on the left
side, as well as “focusing deficits” of her left eye. A neuro-
logical examination performed 2 weeks after symptom on-
set was normal including high-contrast VA (1.25 on both
sides), but refined vision tests revealed a bilateral reduc-
tion of the low-contrast VA (right eye: 0.8; left eye: 0.6).
Brain MRI showed a T2-hyperintense left optic nerve le-
sion and a few bi-frontal non-specific white matter lesions
that did not fulfill the diagnostic criteria for MS. MRI of
the cervicothoracic spinal cord was unremarkable. LP, per-
formed 3 weeks after symptom onset, revealed slight pleo-
cytosis (9 cells/μl) but was otherwise normal; in particular,
OCB were negative. VEP showed normal amplitudes and
delayed P100 latencies in the left eye, but only when dir-
ectly comparing the two eyes with each other (right:
104 ms; left: 112 ms). By contrast, spectral-domain OCT
revealed severe bilateral thinning of the RNFL, most
prominent in the temporal sectors of both eyes (mean
RNFL right: 75 μm, mean RNFL left: 68 μm). Motor,
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somatosensory, and acoustic evoked potentials were unre-
markable. A broad laboratory work-up including ANA,
cANCA, pANCA, and AQP4-IgG, was negative. Anti-
MOG-IgG antibodies were positive at 1:320. MOG-IgG
seropositivity was confirmed by a fixed-cell CBA. While
maintaining breastfeeding the patient was treated with
IVMP for 5 days (1000 mg once daily), which led to a re-
duction of the left-sided retrobulbar pain up to the time of
the last follow-up in 10/2015. At that time, the patient still
refused any long-term immunosuppressant treatment.
Comment: This case is interesting for several reasons.
First, the patient presented with unilateral retrobulbar
pain and headache but normal VA as detected by Snellen
chart and near-normal VEPs. Only additional tests (MRI,
OCT, and low-contrast VA testing) revealed marked bilat-
eral optic nerve damage. Similarly, no impairment of high-
contrast VA but pathological VEPs were found in cases 25
and 27 here as well as in case 2 in part 3 of this series [31].
These cases indicate that subclinical ON needs to be taken
into account also in MOG-IgG-positive patients with
apparently normal VA as routinely detected by a Snellen
score. Second, symptoms compatible with previous epi-
sodes of ON (retrobulbar pain) headache and brainstem
encephalitis (diplopia) had occurred 20 and 18.5 years be-
fore the present attack in this patient, though it remains
unknown whether she was already positive for MOG-IgG
at that time. Similarly, disease started with an attack of uni-
lateral ON at age 13 in another patient in this cohort (see
case 6 in part 3 of this series [31]), which was followed by a
first attack of myelitis only several decades later. Long in-
tervals between first and second attack (up to 17 years)
have also been described in AQP4-IgG-positive patients
[34]. Third, only OCT, not MRI or VEP, was able to dem-
onstrate damage also of the right optic nerve. Fourth, as in
cases 7 and 18 here and in case 12 in part 3 [31], symp-
toms developed post partum, a period associated with an
increased risk for relapse also in MS [108] and in AQP4-
IgG-positive NMOSD [115].
Case 24 – Fifteen attacks of ON with poor response to
treatment and unfavorable bilateral functional visual
outcome. In 2013, this 42-year-old female Caucasian
patient experienced for the first time typical clinical
signs of left-sided ON, with reduced vision, red color
desaturation, and eye pain. Fundoscopic examination
showed a hyperemic and swollen papilla of the left eye.
The VEP amplitudes were reduced on the left side. Fur-
ther diagnostic work-up including anti-AQP4 antibodies,
onconeural antibodies, and immunological screening
was negative. The CSF was normal; in particular, there
was no pleocytosis, no OCB, and no disruption of the
blood-CSF barrier function. MRI of the brain showed an
intense, long-segment gadolinium (Gd) enhancement of
the left optic nerve, but only few non-MS-specific T2-
hyperintense white matter lesions without subclinical
progression or Gd enhancement in follow-up scans.
The brainstem was never involved clinically or radio-
logically. Although the patient reported fluctuating
paresthesia of both legs and left arm, there was no fur-
ther clinical, radiological, or electrophysiological evi-
dence for myelitis.
Due to repeated relapses of isolated ON predominately
affecting the left eye and partial response to steroid treat-
ment, diagnosis of a chronic relapsing inflammatory optic
neuropathy (CRION) was suggested. After 26 months the
patient had experienced altogether 15 relapses of ON,
consecutively affecting both eyes, but never with simultan-
eous bilateral involvement.
Except for two attacks (including the initial one), which
both remitted completely, she responded only partially to
high-dose IVMP treatment. One relapse was treated with
PEX, but to no avail. Successive immunosuppressive treat-
ment with AZA (up to 200 mg per day over 9 months and
cotreatment with oral steroids), MTX, mycophenolate,
and continuous prednisone failed to prevent further
attacks of ON. At the time of the last follow-up, 26 months
after onset, she had a residual VA of < 0.2 in both eyes.
Comment: The poor visual outcome after just 26 months
and the high number of relapses despite regular IVMP
treatment for acute relapses and various IS therapies
illustrate that MOG-IgG-positive ON may take a severe,
relapsing, and sometimes therapy-refractory course. Test-
ing for MOG-IgG should be considered in all patients
with suspected CRION.
V. MOG-IgG-positive recurrent LETM
Case 25 – Recurrent LETM; slightly delayed VEP; no brain
lesions; almost complete recovery. This 22-year-old
Caucasian woman presented with bilateral dys- and
hypesthesia of the lower limbs in 11/2011. The neuro-
logical examination additionally revealed very mild foot
flexor and extensor paresis bilaterally (5-/5) and saddle
anesthesia. MRI of the complete neuroaxis (including
brain, cervical, thoracic, and lumbar spine) was unre-
markable. CSF showed pleocytosis (58 cells/μl) and
slightly elevated protein levels (48.9 mg/dl). After nega-
tive viral and microbiological diagnostics, initial treat-
ment with acyclovir and ceftriaxone was changed to 4 ×
1 g IVMP and, subsequently, oral steroids with tapered
dose reduction. Clinical symptoms receded to slight
plantar dysesthesia with good response to pregabalin.
In 03/2012 a relapse with bilateral dys- and hypesthesia
occurred, this time affecting the upper limbs (fingertips bi-
laterally), lower limbs (thighs), and trunk (T4). Cerebral
MRI again showed no pathologies; spinal MRI, however, re-
vealed two LETM lesions, one stretching from C1 to C4,
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the other from C7 to T9; both showed swelling, the latter
also Gd enhancement. Diagnostic workup again revealed
pleocytosis in the CSF (25 cells/μl) and elevated CSF pro-
tein levels (53.2 mg/dl). OCB and AQP4-IgG were negative.
Serologically, TPO antibodies were positive, but otherwise
there was no indication for another autoimmune disease or
vasculitis. Electrophysiology showed marginal P100 delay
(117 – 118 ms bilaterally) in VEP and reduced amplitudes
in SSEP (pronounced on the right). Again, 4 × 1 g IVMP
with tapered dose reduction was applied. With the sus-
pected diagnosis of AQP4-IgG-negative NMO, AZA was
started at the end of 03/2012. The neurological symptoms
improved under this therapy but the patient developed re-
current genital condyloma, necessitating operative removal.
The patient presented at our hospital for the first time
in 11/2014. She had symptoms of slight gait ataxia,
mainly at night, slight hypesthesia (inner thighs), and
complained of severe fatigue, partly accentuated due to
the recurrent operative procedures during the past few
weeks. Thus the decision was made to switch the medi-
cation to rituximab, and AZA treatment was ended in
12/2014. During the drug-free interval of 3 months, the
patient noted a remarkable clinical amelioration of the
neurological and neuropsychological symptoms and fi-
nally came to be very reserved concerning the initiation
of rituximab. Due to the patient´s concerns, it was de-
cided to continue with close clinical and MRI follow-up.
At the last two follow-up visits (03/2015 and 06/2015)
the patient showed continuous recovery with only
slight residual nocturnal gait ataxia (EDSS 1). MRI
showed no new lesions and no Gd enhancement. At
the first follow-up visit, MOG-IgG were found using
a commercial CBA (Euroimmun) and were confirmed
in the live-cell CBA.
Comment: The good long-term outcome (EDSS 1.0 at
3.5 years after onset) despite three myelitis attacks and
despite the presence of extensive inflammation affecting
the spinal cord over a length of 14 vertebral segments is
remarkable. MOG-IgG-positive myelitis was longitudin-
ally extensive in most of our patients and involved large
parts of or even the entire spinal cord in some cases.
Purely sensory attacks, as observed here, occurred in 13
other cases and, as said before, dysesthesia and pain
were common symptoms in this cohort. Of note, good
response to pregabalin was noted in this patient.
Case 26 – Recurrent LETM; spinal cord biopsy; partial
recovery. This Caucasian man developed a first attack of
myelitis in 12/2013 at age 41, with tetraparesis. Spinal
cord MRI revealed an LETM lesion extending from C3
to C5. Brain MRI showed a right-sided Gd-enhancing
T2 lesion adjacent to the posterior horn of the right ven-
tricle. LP demonstrated mild pleocytosis (23 cells/μl) but
no OCB. A decompression operation was performed in 01/
2014 due to a suspected diagnosis of cervical myelopathy.
However, symptoms worsened again in 04/2014 and a bi-
opsy sample was analyzed to rule out neoplasm and vascu-
litis. Neuropathology revealed T cell infiltration but there
was no specific staining for IgG and complement depos-
ition. Follow-up MRI examinations over a period of 1 year
persistently showed contrast enhancement in the cervical
spinal cord. Two cycles of high-dose IVMP in 10/2014 and
11/2014 with subsequent oral steroid therapy resulted in
only transient improvement. Several tests for AQP4-IgG
were negative. In 02/2015 MOG-IgG was tested for the first
time and was positive at low titer (1:160) in a live-cell assay;
the result was confirmed in a commercial fixed-cell assay
for MOG-IgG (Euroimmun). Broad differential diagnosis
for infectious, (para)neoplastic, and autoimmune conditions
was unremarkable. At follow-up in 02/2015 residual paresis
(EDSS 4) was present; MOG-IgG were again positive at a
titer of 1:160 and were confirmed in a second, commercial
fixed-cell CBA (Euroimmun). There was no clinical, MRI,
or electrophysiological (normal VEP 03/2015) evidence of
optic nerve involvement. In September 2015, just five
months after the first infusion of rituximab, the patient de-
veloped a relapse of acute myelitis with severe paresis. PEX
resulted in only partial recovery. At last follow-up in March
2016, an EDSS of 6 was noted.
Comment: The differential diagnosis of LETM lesions
include, among others, tumors, lymphoma, and spinal
cord compression. Accordingly, reports on (unnecessary)
neurosurgical procedures, including biopsies, exist also in
AQP4-IgG-positive LETM patients [123–126]. Except in
the case of emergency, AQP4-IgG and MOG-IgG should
be excluded using at least two sensitive assays, at least one
of which should be a cell-based assay [8, 29, 124], before
any such procedure is considered.
VI. MOG-IgG-positive monophasic LETM
Case 27 – Single episode of LETM; no brain lesions; par-
tial recovery at discharge. A 23-year-old Caucasian man
presented with a sensory level at T4, local dysesthesia,
mildly positive Babinski reaction, and bladder and erect-
ile dysfunction shortly after an unspecified infection.
MRI showed an LETM lesion extending from C3 to C7
with swelling. Brain MRI was normal. LP revealed lym-
phomonocytic pleocytosis (59 cell/μl) and mild blood-
CSF barrier dysfunction (QAlb 6.96), but no intrathecal
IgG synthesis (no OCB, QIgG normal). Further examina-
tions for infection (Borrelia burgdorferi, Treponema
pallidum, HAV, HBV, HCV, HIV, CMV, EBV, HSV1,
HSV2, FSME, Mycoplasma pneumoniae) or common
autoimmune disorders (ANA, ANCA, rheumatoid fac-
tor, CRP, C3d) were negative except for slightly elevated
phospholipid/glycoprotein beta2 IgG antibodies (IgM
negative). VEP were bilaterally delayed, indicating a
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history of subclinical ON; MRI of the orbit was unre-
vealing. MOG-IgG were positive at a titer of 1:10,240.
Treatment with rocephine, acyclovir and, subsequently,
high-dose steroids and oral tapering was followed by
marked improvement. At discharge, residual mild and
circumscript paresthesia as well as bladder dysfunction
(requiring urinary catheterization) was present.
Comment: In this and two other cases without a history
of clinically apparent ON (case 25 here and case 2 in part
3 of this series [31]), delayed P100 latencies were noted,
suggesting subclinical optic nerve inflammation. The pre-
dictive value of a positive VEP for a future clinical ON re-
lapse in patients with MOG-IgG-positive myelitis is so far
unknown. Of note, the current diagnostic criteria for
AQP4-IgG-negative NMOSD do not take into account
VEP results but only clinical episodes of ON [29].
VII. Postvaccinal ON and myelitis
Case 28 – Recurrent myelitis and ON after vaccination
against tetanus, diphtheria and pertussis resulting in
functional blindness and tetraparesis; poor outcome. A
47-year-old Caucasian woman presented with acute sen-
sorimotor tetraparesis (upper limbs: BMRC grade 4; lower
limbs: BMRC grade 0), transient somnolence, and respira-
tory distress. Symptoms had started 12 days after vaccin-
ation against tetanus, diphtheria, and pertussis (Boostrix®)
and had been preceded by a 2- to 3-day episode of fever
prior to symptom onset. MRI showed a single parieto-
occipital lesion and a longitudinally extensive spinal cord le-
sion extending over 15 vertebral segments (C2 to T9). CSF
examination revealed moderate pleocytosis (210 white cells/
μl) and disturbed blood-CSF barrier function but no CSF-
restricted OCB. The symptoms responded only partially to
IVMP and IA. As MOG-IgG was positive, treatment with ri-
tuximab was started. By 11 days after the first infusion,
spinal cord T2 hyperintensities had resolved almost com-
pletely. However, just 7 weeks after the second infusion of ri-
tuximab and 3 months after onset of the first attack, the
patient developed an episode of simultaneous myelitis and
unilateral optic neuritis leading to severe loss of vision in the
right eye. P100 latencies were delayed in both eyes and am-
plitudes reduced in the right eye. Brain MRI demonstrated
an increase in size of the parieto-occipital lesion. Spinal MRI
showed T2 hyperintensities from C7 to T8, predominantly
in the posterior columns. Treatment with IVMP and IA was
followed by incomplete remission of the symptoms. Just
48 days after onset of the second attack, the patient was re-
admitted with a new attack of unilateral ON in the left eye
resulting in almost complete visual loss (VA 0.05). Treat-
ment with IVMP, IA, and cyclophosphamide led only to par-
tial recovery (VA 0.16 at discharge). At last follow-up, severe
spastic paralysis of the lower limbs and an EDSS score of 8
was documented.
Comment: Disease onset in this patient followed vaccin-
ation with a polyvalent vaccine against tetanus, diphtheria,
and pertussis. Although a causal link between the two
events cannot be proved, the close temporal association is
highly suggestive of vaccine-mediated immune activation.
Of particular note, symptoms also started within 2 weeks
after a polyvalent vaccination against tetanus, diphtheria,
and pertussis (as well as polio and influenza virus) in a sec-
ond MOG-IgG-positive patient of this cohort (see case 8 in
part 3 [120]). Whether molecular mimicry between vaccine
epitopes and neural antigens played a role or whether vac-
cination only indirectly triggered or promoted the immune
reaction against MOG is currently unknown but certainly
warrants further investigation.
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